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ABSTRACT
A Tn7-based transposition system carrying a kanamycin resistance gene has been
used to disrupt a known virulence gene of Brucella melitensis 16M and Brucella abortus
2308 in-vitro. The suicide plasmid pBAvirB1::kan-29 was created, in part, by cloning the
B. abortus virB1 gene into a vector that is not stably maintained in Brucella spp. The
cloned virB1 gene was then mutagenized by in-vitro transposition of a Tn7-based
transposon. This construct was used in-vivo to insert a disrupted virB1 gene in place of
the wild type virB1 found in B. abortus 2308 and B. melitensis 16M by homologous
recombination. The resulting virB1 mutant brucellae exhibited resistance to kanamycin,
decreased survival in murine macrophages and attenuated virulence in a BALB/c mouse
model. This method is proposed to be a simple, efficient means of generating gene
knockouts in Brucella spp., and may be useful in targeting virulence factors for the
creation of live, attenuated vaccines. The genus Brucella consists of bacteria that are
facultative intracellular pathogens. Individuals in this genus of Gram-negative
coccobacilli are responsible for causing late term spontaneous abortion in cattle and goats
as well as the human disease brucellosis (undulant fever). The success of Brucella is
dependent on their ability to invade, survive and multiply within phagocytes. The virB
operon, consisting of eleven genes in most Brucella species, is thought to contribute to a
type IV secretion system responsible for maintaining infection in a mammalian host.
Further results of this study suggest that the Brucella virB1 gene product, like its
Agrobacterium counterpart, may not be essential for virulence; disruption of the Brucella
virB1 gene results in a one to two log decrease in intracellular survival at forty-eight
hours in an in-vitro macrophage model and by four weeks in an in-vivo mouse model.

vii

CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW
During the late nineteenth century a German physician named Robert Koch set
out to prove the germ theory of disease, which had been stated by Girolamo Fracastoro of
Verona over three hundred years earlier. From his studies with anthrax, Koch formulated
a set of postulates that are still used today for the identification of etiological agents
(Atlas 1997). With the connection between microorganisms and disease established there
came an understanding of vaccination, the discovery of antimicrobial agents and the
study of virology and immunology. As a result of these and other technological
advances, the average human life expectancy rose dramatically and once common
ailments such as measles, diphtheria, pneumonia and tuberculosis became treatable and
sometimes curable. One such treatable disease of humans and a wide variety of
mammals is brucellosis, which is caused by bacteria of the genus Brucella.
While stationed on the island of Malta, the British army physician, David Bruce,
was the first to successfully isolate and culture Micrococcus melitensis in 1897, which
was later renamed Brucella melitensis in his honor (Spink 1956; Dalrymple-Champneys
1960). As many British sailors discovered, Brucella infection may lead to the
debilitating, chronic disease known as brucellosis. If it is not treated with antibiotics,
brucellosis can result in lymphoid organ inflammation together with bone and joint
problems, and in rare cases death (Spink 1956; Dalrymple-Champneys 1960; Thimm
1982; FAO/WHO 1986; Jawetz, Melnick et al. 1989; Madkour 1989; Paul 1993; Young
1995; Comerci, Martinez-Lorenzo et al. 2001; DelVecchio, Kapatral et al. 2002).
Brucella is also responsible for late-term abortion in several domestic and wild
mammals, including swine, goats, cattle, sheep, bison and elk (Spink 1956; DalrympleChampneys 1960; WHO/EMC 1998). Although the incidence of Brucella infection has
1

been greatly reduced or eliminated in many countries, brucellosis is still the world’s most
widespread zoonoses and is prevalent in many underdeveloped nations (Ruben, Band et
al. 1991). Of additional importance is the designation of Brucella as a biosafety level III
disease organism and its use as an agent of biological warfare. According to the Centers
for Disease Control and Prevention (CDC) in Atlanta, which considers Brucella a select
agent with Class B status as a biological threat (same category as the agents which cause
Q fever and encephalitis), brucellae are listed among the top ten most important
biological warfare agents for public health preparedness (Frederick, Takafuji et al. 1997;
Rotz, Khan et al. 2002). Outlined in a report by the WHO in 1970 (Health Aspects of
Chemical and Biological Weapons), it was calculated that upon biological attack,
brucellae have the potential to incapacitate as many people as an equivalent dose of
Bacillus anthracis or Coxiella burnetii (causative agent of Q fever) (as reviewed by
Christopher, Cieslak et al. 1997; Madigan, Martinko et al. 2000). But while vaccines
have been developed to protect against other biological diseases such as tularemia, Q
fever and anthrax, a Brucella vaccine has been illusive, being unsuitable for human use
(Huxsoll et al. 1989 as cited in Franz, Parrot et al. 1997).
1.1 General Characteristics of Brucella spp.
Brucellae are small, non-motile, Gram-negative coccobacilli about 0.6µm - 1.5µm
in length and 0.5µm - 0.7µm in width, found in the α2 subdivision of the phylum
Proteobacteria (Thimm 1982; FAO/WHO 1986; Moreno, Stackebrandt et al. 1990). The
majority of species in this subdivision are associated with eukaryotes as endosymbionts
or pathogens (Fig. 1) (Ugalde 1999; Sieira, Comerci et al. 2000). Individuals in the
genus Brucella are intracellular pathogens of mammals including humans (Dalrymple-
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Champneys 1960). All species of Brucella are non-spore forming and aerobic, except for
B. abortus and B. ovis, which are carboxyphilic, requiring an increased CO2 tension of
5% for optimal growth (Thimm 1982; FAO/WHO 1986; Thoen, Enright et al. 1993).
Agrobacterium vitis
A. rubi
Rhizobium. meliloti
Rhizobium
fredii

A. tumefaciens

beta and gamma

Rhizobium
leguminosarum
Bradyrhizobium japonicum

A. rhizogenes

Phyllobacterium
myrsinacearum

Mycoplana
dimorpha

Brucella spp.

Rhodobacter
capsulatus

Ochrobactrum anthropi

Rhodobacter sphaeroides
Bartonella quintana

Fig. 1. Partial phylogenetic tree of the α-2 subgroup of Proteobacteria with the addition
of Rhodobacter (α-3 subgroup) (redrawn from Jumas-Bilak, Michaux-Charachon et
al. 1998b).
Brucellae are currently categorized into at least six different species
encompassing 18 biovars, with several undesignated strains that infect marine mammals
(Bricker 2000; Moreno and Moriyon 2002). There is evidence, however, to suggest that
the genus is monospecific with B. melitensis considered the type species (Verger,
Grimont et al. 1985; Michaux-Charachon, Bourg et al. 1997). Each species is specialized
to an existence within a particular mammal host: B. abortus in cattle, bison and elk; B.
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melitensis in goats and sheep; B. suis in pigs; B. canis in dogs; B. ovis in sheep and B.
neotomae has been found in the desert wood rat (W. Wundt 1956 and FAO/WHO 1971
as cited in Thimm 1982; FAO/WHO 1986; Madkour 1989). None of the Brucella spp.
have plasmids and all species contain 2 chromosomes with a G + C content between 5759%, except for B. suis biovar 3, which has a single combined chromosome (Michaux,
Paillisson et al. 1993; Corbel 1997; Michaux-Charachon et al. 1997; Jumas-Bilak,
Michaux-Charachon et al. 1998a; O'Callaghan, Cazevieille et al. 1999; DelVecchio et al.
2002).
Brucellae are ubiquitous, and can be found in almost every country and
environment where there are mammals, from the Mediterranean basin to Japan and North
America through parts of Mexico, Central and South America to Australia (Thimm 1982;
Young 1995). According to Madkour (1989), only 17 countries have been declared
Brucella-free as of 1989. Brucellosis is a disease problem in many underdeveloped areas
such as Africa, China and the Middle East as well as Latin America (Ruben et al. 1991;
WHO/EMC 1998); however, the incidence of Brucella infection in both man and animal
has been greatly reduced or eliminated in most developed nations (Corbel 1997).
In those affected areas, Brucella is of economic importance because it readily
causes late term abortion, decreased milk production and infertility in infected animals.
Brucella abortus infection may cause late term abortion and sterility in cattle, (Bang’s
disease) (Huddleson 1947a; Spink 1956; Cloeckaert, Verger et al. 1996b) while B. suis
infects swine with resulting abortion in pregnant females and orchitis, epididymitis, and
sterility in males (Manthei 1948 as cited in Spink 1956; Dalrymple-Champneys 1960).
Brucella ovis is responsible for abortion and sterility in sheep (Buddle 1956; Cloeckaert
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et al. 1996b) while B. melitensis is a causative agent of abortion in both goats and sheep
(Dalrymple-Champneys 1960).
1.2 Brucella spp. Infection and Dissemination
Human transmission and Brucella infection may occur by inhalation of infectious
aerosols, passage across mucous membranes, through a percutaneous route such as cracks
or cuts in the skin or even through unbroken skin (Kaufmann, Fox et al. 1980; Thimm
1982; Smith and Ficht 1990; Ruben et al. 1991). The route of Brucella dissemination
throughout the body is dependent on dedicated phagocytic cells such as macrophages and
neutrophils (Mims 1987; Enright 1990). Once the bacterium is engulfed by a phagocyte
it resists bactericidal mechanisms and begins to multiply while it is transported through
the lymphatic system and localized in lymph nodes (Mims 1987; Jawetz et al. 1989).
Brucellae multiply within lymph nodes causing hemorrhage at 2 to 3 weeks postinfection and then invade the blood stream leading to eventual bacteremia and
dissemination throughout the body (Enright 1990; Thoen et al. 1993).
Studies reveal that in ruminants and humans brucellae localize to the reticuloendothelial system, including the liver, spleen, kidneys, mammary glands and bone
marrow and to nontraditional phagocytic cells such as those of the brain, endocardium,
bones and joints (Spink 1956; Dalrymple-Champneys 1960; Smith and Ficht 1990).
Brucellae may colonize both the male and pregnant female reproductive tracts, especially
the chorionic trophoblasts of the placenta (Smith 1919; Spink 1956; DalrympleChampneys 1960; Meador and Deyoe 1989).
1.3 Brucella spp. Reproductive Tropism
In the ruminant, brucellae have a tropism for reproductive organs in both males
and females locating to the testis, uterus and especially placental tissues (Smith 1919;
5

Meador and Deyoe 1989; Enright 1990; Samartino and Enright 1993). Placental
destruction and necrosis resulting in ulcerated chorionic membranes releases large
numbers of Brucella into the uterine lumen that are transferred to chorionic villi and fetal
tissues (Anderson, Meador et al. 1986a, b; Enright 1990). Brucella induced abortion is
thought to be caused by placentitis followed by vasculitis, decreased placental function
(Anderson et al. 1986b; Enright 1990), and direct transmission to the fetus (Payne 1959;
Thoen et al. 1993). But as noted by Enright (1990), even with severe placentitis, the
endometrium is left largely untouched. A combination of factors, in addition to
decreased placental function, appears to contribute to abortion. Possibilities include fetal
stress due to steroid production and the presence of a weak Brucella endotoxin. Brucella
infection of both sheep and cows results in increased cortisol production with a
subsequent decrease in progesterone and increase in estrogen secretion by the placenta
(Enright 1990). This sudden change in hormonal levels results in increased endometrial
PGF2α production leading to premature delivery or possibly abortion (Liggins 1981 as
cited in Enright 1990; Elzer, Phillips et al. 1996).
Additionally, the ruminant fetus’ immune system is less able to control Brucella
infection compared to the adult (Enright 1990). Large granulomatous lesions, composed
of macrophages, epithelioid cells, and other polymorphs, form in infected fetal tissues
such as the lung, kidney, liver and lymphoid tissues. Fetal infection is characterized by
elevated cortisol production, presumably due to fetal stress, together with an increase in
the neutrophil population and a decrease in the number of lymphocytes and eosinophils.
The presence of a Brucella endotoxin, consisting of lipopolysaccharide (LPS), is also
thought to contribute to abortion, possibly due to vasculitis and placentomal lesions

6

(Anderson et al. 1986b; Huddelson 1953 and Molello 1963 as reviewed by Samartino and
Enright 1993). This notion is plausible since LPS and lipid A from other Gram-negative
bacteria have abortive properties when present in living microorganisms or administered
in purified form (Enright 1990). Presently, however, the process of abortion due to
Brucella infection and colonization is still not completely understood.
Why brucellae have a tropism for reproductive organs is still debated. An initially
accepted theory held that because brucellae preferentially metabolize the sugar erythritol,
they locate to areas which contain this carbohydrate, such as the placenta (Pearce 1962 as
reviewed by Tripathi, Bhatnagar et al. 1977; Samartino and Enright 1993). Brucella spp.
share this ability to metabolize erythritol with only one other pathogenic bacterium,
Serratia marcescens (Slotnick and Dougherty 1972). Several studies have supported this
theory, such as those of Tripathi et al. (1977), and Keppie et al. (1965) (as reviewed by
Tripathi et al. 1977). Recently Sangari et al. (2000) and DelVecchio et al. (2002) have
identified the genes responsible for the erythritol catabolic pathway in Brucella. It was
proposed that the absence of erythritol in the placentas of humans, rats, mice, rabbits and
guinea-pigs could explain the rare occurrence of Brucella in the reproductive systems of
these animals (Keppie 1964 as cited in Samartino and Enright 1993). However, it has
been shown that Brucella can infect the placenta of all these species including humans
(Kniazeff, Elberg et al. 1964; Bosseray 1980; Madkour 1989; Samartino and Enright
1993). Additionally, Brucella erythritol catabolizing gene (ery) knockout strains proved
to be just as virulent as wild type Brucella (Elzer 2002a). Thus, it appears that the ability
to catabolize erythritol may not be the determining factor that allows Brucella to colonize
the placenta and cause abortion, but it may confer an advantage.
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1.4 Brucella Infection and Man
Brucella is also an important zoonotic pathogen, ranking among the world’s top
five most common bacterial zoonoses (Sola-Landa, Pizzaro-Cerda et al. 1998). Members
of the genus known to infect man include B. melitensis, B. abortus, B. suis and B. canis
(Spink 1956; Thimm 1982; Ramacciotti 1984; Madkour 1989; Elzer 2002a). Of the six
known species of Brucella, B. melitensis is considered the most infectious and virulent to
man, followed by B. suis and then B. abortus (Table 1) (Spink 1956; Madkour 1989;
Smith and Ficht 1990).
Table 1. Relative Brucella infectious dose for man of the four most virulent species
(Young 1995; Elzer 2002a).
Virulence to Humans
Most Virulent

Least Virulent

Species

Relative infectious dose

B. melitensis

~1-10 organisms

B. suis

~1000

B. abortus

>100,000

B. canis

~1,000,000

The most common causes of human infection include laboratory acquired infection,
ingestion of unpasteurized milk, contaminated cheese, and contact with diseased animals,
especially placental tissues (Dalrymple-Champneys 1960; Young 1975; Fox and
Kaufmann 1977; Thimm 1982; 1991; Ruben et al. 1991; Corbel 1997; Hong, Tsolis et al.
2000).
Brucella infection in man causes a systemic, febrile disease known as brucellosis.
It has been referred to as undulant fever, Malta fever (B. melitensis), Mediterranean
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remittent fever, Gibraltar fever, Cyprus fever and neapolitan fever, among others (Spink
1956; Thimm 1982; Jawetz et al. 1989; Madkour 1989). Acute, human brucellosis is
characterized by a cyclic fever, shaking chills, profuse, drenching night and evening
sweats, weakness, weight loss, nervousness, joint pain, insomnia, headache and
respiratory trouble in the short term (Spink 1956; FAO/WHO 1986; Jawetz et al. 1989;
Madkour 1989; DelVecchio et al. 2002). Other clinical short term signs include
lymphadenopathy, splenomegaly, hepatomegaly, skin rash, depression and mental
fatigue, with CNS invasion occurring in < 2% of cases (Spink 1956; Madkour 1989;
Young 1995). Chronic, long term complications include weakness, sacroiliitis, orchitis,
epididymo-orchitis, spondylitis, osteomyelitis, bursitis, bone and joint infection,
dementia, neurological disorders and relapse with recurrent bacteremia (Spink 1956;
Dalrymple-Champneys 1960; Thimm 1982; FAO/WHO 1986; Jawetz et al. 1989; Young
1995; Comerci et al. 2001). Severe cases of brucellosis can demonstrate as bronchitis,
meningitis and in < 2% of all cases, endocarditis, which is responsible for the majority of
Brucella-related deaths (Bouza 1987 as cited in Hart, Morgan et al. 1951; DalrympleChampneys 1960; Al-Harthi 1989; Young 1995; Comerci et al. 2001).
Full recovery from brucellosis is possible with antibiotic therapy. Rifampicin
(600-900mg/day) and doxycycline (200mg/day) given for 6 weeks is the most effective
treatment for eliminating Brucella infection (FAO/WHO 1986). The incubation period
between infection and outward clinical signs is thought to average 1-3 weeks, however it
may be as long as several months (Madkour 1989). According to an FAO/WHO report
(1986), natural recovery from brucellosis of average severity takes 1-3 months with
weakness and fatigue lasting much longer. As a result of this ability to incapacitate its
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host, some species of Brucella have been investigated as biological warfare agents by
several governments including the United States (Christopher et al. 1997; Franz et al.
1997). Beginning in 1942 and under the direction of the War Reserve Service, several
potential pathogenic and nonpathogenic biological agents, including Brucella suis, were
tested as candidates for weaponization (Christopher et al. 1997). By 1954 B. suis was
loaded into biological cluster bombs for use by the U.S. Airforce (Franz et al. 1997).
1.5 Brucella Intracellular Colonization
1.5.1 Brucella General Intracellular Characteristics
Members of the genus Brucella do not evade phagocytosis by professional
phagocytes. According to Spink (1956), phagocytosis of brucellae by macrophages and
polymorphonuclear (PMN) cells may be necessary for protection and dissemination of
the bacterium throughout the host. Brucellae are non-motile and readily ingested by
macrophages where they multiply, eventually establishing infection within both
professional and non-professional phagocytic cells (Smith and Ficht 1990). Other
virulent facultative intracellular pathogens with this ability to colonize phagocytic cells
include Mycobacterium, Legionella, Shigella, Listeria, Salmonella, Yersinia, Nocardia
and possibly Neisseria (Kiderlen, Kaufmann et al. 1984; Frenchick, Markham et al. 1985;
Mims 1987; Salyers and Whitt 1994; Russell 2000; Cianciotto 2001). Exactly how
brucellae withstand the bactericidal environment of such cells as macrophages and
neutrophils is not entirely understood; however, there appears to be more than one
mechanism involved. Studies conducted by Detilleux, Deyoe et al. (1990a, b, 1991)
show that brucellae do not induce their own uptake by non-phagocytic cells. After
phagocytosis, brucellae are found in coated pits, suggesting they are phagocytized by
non-professional phagocytes, such as Vero cells, through a receptor-mediated process
10

that has not yet been elucidated. One particular study has confirmed these observations
with non-professional phagocytes and provided new evidence that Brucella uptake into
macrophages is also receptor mediated. Using transposon mutagenesis, Sola-Landa et al.
(1998) have uncovered a possible two component sensory and regulatory (BvrR-BvrS)
system employed by B. abortus, which may be responsible for invasion, intracellular
survival and replication within Hela cells and macrophages. The BvrR-BvrS system of
Brucella is closely related to similar sensory/regulatory systems in Rhizobium meliloti
(Chvl-ExoS) and Agrobacterium tumefaciens (Chvl-ChvG) (Sola-Landa et al. 1998). It
appears that the Brucella BvrR-BvrS system is responsible for outer membrane properties
that control bacterial susceptibility to polycations and surfactants, host cell penetration
and invasion, and intracellular survival and phagosomal trafficking (Sola-Landa et al.
1998).
1.5.2 Brucella Within Professional Phagocytes
Within professional phagocytes, such as macrophages, brucellae appear to survive
and multiply within the phagosome and phago-lysosome, similar to pathogens like
Leishmania spp. and Coxiella burnetti (Harmon, Adams et al. 1988; Rabinovitch 1996 as
cited in Sinai and Joiner 1997; Porte, Liautard et al. 1999). Recent work by Rittig,
Alvarez-Martinez et al. (2001) suggests that when brucellae (B. suis and B. melitensis)
are phagocytized by human monocytes, they are sequestered in phagosomes with either
tightly (TP) or loosely (SP) apposed walls. Brucellae found in the TP phagosomes
readily survive acidification whereas brucellae found in SP phagosomes are killed in the
acidic environment resulting from phagosome-lysosome fusion.
Once phagosome-lysosome fusion occurs, brucellae appear to be resistant to
degradation at a pH of 3.2-4.0 and begin multiplying within the acidified compartment
11

(Kulakov, Guigue-Talet et al. 1997; Porte et al. 1999; Arenas, Staskevich et al. 2000;
Endley, McMurray et al. 2001). This resistance to lysosomal degradation is also seen in
other bacteria such as Mycobacterium lepraemurium, which is protected by a
hydrophobic mycoside capsule, and Salmonella typhimurium (Mims 1987). Evidence
suggests that acidification of the Brucella containing phagosome promotes the synthesis
of bacterial stress proteins including GroEL and DnaK which are essential for replication
of the bacteria within macrophages (Lin and Ficht 1995; Kohler, Teyssier et al. 1996;
Rafie-Kolpin, Essenberg et al. 1996; Porte et al. 1999; Arenas et al. 2000; Rittig,
Alvarez-Martinez et al. 2001; Boschiroli, Ouahrani-Bettache et al. 2002). Brucellae
share this unique environment for transcriptional activation with at least four other
pathogens such as Leishmania, Coxiella, Legionella pneumophila (Sturgill-Koszychi and
Swanson 2000), and Salmonella typhimurium. Upon phagosome acidification
Salmonella activates pag gene expression, which are virulence and survival genes under
the direction of the phoP/phoQ sensory/regulaory system that are regulated by stressful
conditions such as carbon limitation and low pH typically found within the phagosome of
a macrophage (Aranda, Swanson et al. 1992; Salyers and Whitt 1994; Rathman, Sjaastad
et al. 1996; Joiner 1997; Russell 2000; Cianciotto 2001; Rittig et al. 2001; Boschiroli et
al. 2002).
1.5.2.1 Brucellacidal Activity of PMNs and Macrophages
Virulent strains of Brucella can readily invade and multiply within both
macrophages and PMN cells (Young 1995). Macrophages, however, are considered the
primary phagocytic host (Mims 1987; Madkour 1989). Why brucellae are rarely found in
PMN cells such as neutrophils probably has to do with both their increased bactericidal
activity and limited life span (Madkour 1989; Thoen et al. 1993). PMN cells are known
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to produce a larger quantity of antimicrobial oxygen species, thus making them more
effective than monocytes or macrophages at killing certain fungi and bacteria (Mims
1987). In addition, activation may be required for full macrophage antimicrobial activity,
as evidenced by the parasites Leishmania, Listeria and Toxoplasma gondii, which can
survive phagocytosis by non-activated macrophages (Mims 1987). However, compared
to Listeria, Brucella is more resistant to killing by activated macrophages (FAO/WHO
1986). The limited life span of a PMN, usually two to three days in man, compared to
several weeks or months for macrophages, may also be a limiting factor, not allowing for
Brucella replication and persistence (Mims 1987; Atlas 1997). The basic bactericidal
mechanisms of both macrophages and PMN cells will be discussed in section 1.6.
1.5.3 Brucella Within Non-Professional Phagocytes
Within non-professional phagocytes, like Vero cells, Hela cells and trophoblasts,
Brucella takes a different course altogether, and is not solely located in phagosomes or
phago-lysosomes. As with professional phagocytic cells, brucellae may be found within
phagosomes of non-dedicated phagocytic cells (Detilleux, Deyoe et al. 1990a; PizzaroCerda, Moreno et al. 1998). According to Detilleux et al. (1990a), the fate of these
brucellae after phagosome-lysosome fusion appears to be death and degradation. An
important discovery made by Anderson et al. (1986a, b) in two studies revealed that
within the placenta of goats, B. abortus is endocytosed by erythrophagocytic trophoblasts
and subsequently localize and multiply within the rough endoplasmic reticulum (RER) of
chorioallantoic trophoblasts. This localization of brucellae to cisternae of the RER or ER
(endoplasmic reticulum)-like structures has also been well established in other nonphagocytic cells including Vero cells (Detilleux, Deyoe et al. 1990b; Detilleux et al.
1990a; Detilleux, Deyoe et al. 1991), Hela cells (Pizzaro-Cerda et al. 1998; Delrue,
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Martinez-Lorenzo et al. 2001), as well as in further experiments using trophoblasts
(Anderson et al. 1986a, b; Samartino and Enright 1993). The only other bacterium that
finds a similar, although not identical, ER-like intracellular niche is Legionella
pneumophila (Katz and Hashemi 1982; Horwitz 1983). The purpose for RER
colonization by Brucella has only been speculative, but possibilities include use of
trophoblastic RER produced proteins for bacterial metabolism or as glycoprotein
components of the bacterial membrane (Anderson et al. 1986b).
1.6 Brucella Intracellular Survival
1.6.1 Intracellular Environmental Conditions
Once phagocytized by macrophages or PMN cells, brucellae must endure an
onslaught of bactericidal elements. Antimicrobial mechanisms available to phagocytes
can be separated into those that are oxygen-dependent, non-oxygen dependent or nitrogen
dependent (Mims 1987; Atlas 1997). Once phagocytized, brucellae encounter an initial
oxidative burst which generates reactive oxygen intermediates such as superoxide anions,
hydrogen peroxide and hydroxyl radicals (Mims 1987). In addition, PMN cells and
circulating monocytes catalyze the myeloperoxidase-mediated halogenation of hydrogen
peroxide, leading to the production of hypohalides (OCL-) and singlet oxygen (Elsbach
and Weiss 1983; Mims 1987; Baldwin, Jiang et al. 1993; Paul 1993). These oxygen and
halogenated radicals damage DNA, proteins and bacterial membrane lipids (Mims 1987;
Paul 1993). Nitrogen-dependent antimicrobial activity includes the production of
reactive nitrogen intermediates like nitrate, nitrite and nitric oxide (Atlas 1997).
Brucellae must also contend with oxygen independent bactericidal mechanisms
used by professional phagocytes that result from phagosome-lysosome fusion and
acidification of the phagosome to a pH of 3.5 (Mims 1987; Porte et al. 1999).
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Phagocytes release hydrolytic enzymes, such as lysozyme and acid hydrolases, into the
phagosome as well as antimicrobial agents like defensins and cationic proteins which are
found in PMN cells and some macrophages (Mims 1987; Paul 1993; Porte et al. 1999).
Professional phagocytes also use nutritional deprivation against ingested microbes. PMN
cells secrete a B12-binding protein, while both macrophages and PMN cells discharge
lactoferrin into the phago-lysosome, which competes with intracellular bacteria for free
iron (Mims 1987; Atlas 1997).
1.6.2 Intracellular Survival Mechanisms
1.6.2.1 Brucella Manipulation of Phagosomal Maturation
After phagocytosis, Brucella spp., like Mycobacterium, Legionella, Chlamydia,
Toxoplasma, Salmonella and Listeria, alter the process of phagosome maturation and
phagosome acidification (Aranda et al. 1992; Alvarez-Dominguez, Roberts et al. 1997;
Sinai and Joiner 1997; Arenas et al. 2000). Upon phagocytosis by macrophages, B.
abortus may alter phagosomal maturation and intracellular transport in at least half of
their vacuoles, significantly delaying interaction with lysosomes (Arenas et al. 2000;
Endley et al. 2001; Rittig et al. 2001). Recently, Naroeni, Jouy et al. (2001) have shown
with B. suis that delayed phagosomal maturation may be due to a phagosomal membrane
modification that prevents or delays lysosomal recognition. This modification is believed
to be due to an active process by which brucellae alter the phagosomal membrane since
killed brucellae do not cause delayed phagosomal maturation. Frenchick et al. (1985)
suggest this modification is not associated with the Brucella LPS.
1.6.2.2 Brucella Inhibition of Phagocyte Degranulation
Instead of directly challenging the host’s natural bactericidal machinery, brucellae
may use stealth to establish an intracellular replication niche. Studies conducted by Riley
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and Robertson (1984a, b) suggest that virulent, smooth strains of B. abortus fail to
stimulate human or bovine PMN cell degranulation at levels comparable to extracellular
parasites such as Staphylococcus epidermidis. Intracellular degranulation by PMN cells
normally involves the fusion of microbe-containing phagosomes with lysosomes,
releasing bactericidal agents such as reactive oxygen species, proteases and defensins
(Riley and Robertson 1984b, a). Furthermore, the level of degranulation caused by
glutaraldehyde-killed B. abortus was comparable to viable B. abortus, suggesting that a
surface molecule of Brucella either allows the bacteria to enter the macrophage
undetected or inhibits normal degranulation by some unknown mechanism (Riley and
Robertson 1984b, a). Other researchers have obtained similar results showing inhibited
degranulation while also using bovine PMN cells (Canning, Roth et al. 1986).
A major departure from the theory of a surface macromolecule as the inhibitor of
degranulation is the identification of two molecules, produced by live B. abortus, which
alone suppress PMN cell degranulation (Canning, Roth et al. 1985; Canning et al. 1986).
Adenine and 5’-guanosine monophosphate (GMP) were found to inhibit up to 80% and
65% respectively, of the release of peroxidase-positive granules from bovine PMN cells
(Canning et al. 1986). Similar results have been obtained in experiments with another
pathogen, Haemophilus somnus (Chiang, Kaeberle et al. 1986), where the secretion of
GMP and adenine also inhibit PMN function (Canning et al. 1986).
1.6.2.3 Brucella Inhibition of Macrophage Activation
Macrophage activation is essential for immune control of microbial infections
(Mims 1987). Activated macrophages have increased lysosomal enzyme content and
bactericidal mechanisms, which are necessary for controlling intracellular pathogens
(Cossart, Boquet et al. 2000). Thus, activated as opposed to non-activated macrophages
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have an enhanced ability to resist infection and/or manage Brucella, mycobacteria,
Listeria monocytogenes, protozoans such as Toxoplasma gondii and Leishmania, as well
as some viral agents (Pomales-Lebron and Stinebring 1957; Fitzgeorge, Solotorovsky et
al. 1967; Ralston and Elberg 1968; Mims 1987; Unane 2000). Activation may occur
through a T-cell dependent or independent manner. The T-cell independent pathway
relies on a cytokine cascade that begins when the macrophage encounters a pathogen,
triggering the release of interleukin-12 (IL-12) and tumor necrosis factor-α (TNF-α). IL12 and/or TNF-α stimulate natural killer (NK) cells to secrete interferon gamma (IFN-γ)
that, in turn, activates other macrophages (Paul 1993; Unane 2000). The T-cell
dependent pathway involves the digestion and presentation of bacterial proteins on the
surface of macrophages and other antigen presenting cells (APCs), which are attached to
major histocompatibility complexes (MHCs). Bacterial antigens bound to these MHC
class II molecules, in the presence of IL-12, stimulate CD4+ cell differentiation into Th1
(T-helper) cells that subsequently release IFN-γ which activates macrophages (Salyers
and Whitt 1994; Unane 2000).
1.6.2.4 Brucella Inhibition of Phagocyte Cytokine Signaling
The importance of both IFN-γ and TNF-α to macrophage activation and the
control of Brucella infection have been shown in numerous studies (Jones and Winter
1992; Stevens, G. W. Pugh et al. 1992; Baldwin et al. 1993; Jiang and Baldwin 1993;
Jiang, Leonard et al. 1993; Baldwin and Winter 1994; Caron, Peyrard et al. 1994;
Murphy, Parent et al. 2001). Moreover, Brucella survival within human macrophagederived cells appears to be at least partially dependent on it’s ability to inhibit the
secretion of TNF-α and thus avoid macrophage activation via IFN-γ (Caron et al. 1994;
Caron, Gross et al. 1996). Precedent for this virulence factor is found in other pathogens
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such as Yersinia pestis, Listeria monocytogenes, Bacillus anthracis, and Mycobacterium
avium all of which inhibit TNF-α production by their hosts (Furney, Skinner et al. 1992;
Ugalde 1999). Interestingly, Rhodopseudomonas sphaeroides, a purple, nonsulfur
bacteria found in α-Proteobacteria produces a lipid A that also inhibits TNF- α
production by macrophages (Takayama, Qureshi et al. 1989; Madigan et al. 2000).
Studies by Caron et al. (1994, 1996) found that B. suis infected human-derived
macrophages could not accumulate TNF-α mRNA, and that Brucella LPS was not
responsible. They also concluded that inhibition of TNF-α production was the result of
an active process by the bacterium since chloramphenicol treated and killed B. suis did
not trigger human macrophages to secrete TNF-α. Furthermore, Caron et al. (1996) have
tentatively identified the Brucella inhibitor of TNF-α as a protein, based on its protease
and heat sensitivity, of 45 to 50 kDa.
Research by Zhan, Liu et al. (1996) has reevaluated the centrality of TNF-α to
macrophage activation and brucellacidal activity. Using a mouse model, they determined
that the most important cytokine for macrophage activation is not TNF-α, but rather IL12. Zhan et al. (1996) assert that although both TNF-α and IFN-γ are necessary for
complete control of Brucella infection, TNF-α contributes to brucellacidal activity by an
IFN-γ independent pathway, whereas IL-12 is mainly responsible for the activation of
NK cells and secretion of IFN-γ leading to macrophage activation. This view is
supported by work from Zhou, Miller et al. (1998), who also suggest TNF-α induced
macrophage activation is independent of IFN-γ. Additionally, recent work proposes that
monocyte programmed cell death is inhibited by brucellae through a TNF-α and LPSindependent mechanism (Gross, Terraza et al. 2000). Specifically, Gross et al. (2000)
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assert that the apoptotic affect of IFN-γ towards human phagocytic monocytes is blocked
after B. suis infection. An opposing view, however, is held by Zhan and Cheers (1998)
and Flesch et al. (1995) (as reviewed by Zhan and Cheers 1998) who advocate a direct
relationship among TNF- α, IL-12 and IFN- γ.
1.6.2.5 Brucella Outer Membrane
The Brucella outer membrane has no pili, fimbriae or capsular components, but
simply contains phospholipids, outer membrane proteins (Omp), and LPS, of which only
the O-polysaccharide component of the LPS is considered a true virulence factor (Smith
and Ficht 1990; Cloeckaert, Verger et al. 1996a; Elzer 2002a). Brucellae also have a high
content of ornithine lipids (17-32% of total lipid) in their outer membrane (Martin and
Hancock 1990). Ornithine lipids are neutral lipids made up of ornithine, ethylene glycol
and fatty acids, they resist hydrolysis by phosopholipases and possibly serve as a
stabilizing agent for Brucella conveying resistance to EDTA and polycations by shielding
negatively charged groups in the LPS (Cherwonogrodsky, Dubray et al. 1990; Moreno
and Moriyon 2002).
1.6.2.5.1 Brucella LPS
The lipopolysaccharide of Brucella contains the main components of extracellular
toxicity, lipid A, and one of the major Brucella antigens, the O-polysaccharide. The
presence or absence of the O-polysaccharide/antigen in the LPS layer is the molecular
basis of Brucella smooth and non-smooth (mucoid or rough) morphology (Caroff, Bundle
et al. 1984; FAO/WHO 1986; Perry and Bundle 1990; Smith and Ficht 1990; Corbel
1997; Ugalde, Czibener et al. 2000). The Brucella smooth phenotype is naturally more
virulent, while non-smooth brucellae are normally avirulent (Riley and Robertson 1984b,
a; Young, Borchert et al. 1985; FAO/WHO 1986; Harmon et al. 1988; Smith and Ficht
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1990; Roop II 1991; Rasool, Freer et al. 1992; Thoen et al. 1993; Baldwin and Winter
1994; Kulakov et al. 1997). According to Riley and Robertson (1984a), B. abortus
smooth and non-smooth strains elicit similar amounts of degranulation from bovine and
human PMN cells, however, the smooth strains, unlike the non-smooth versions, are
resistant to the phagocyte’s microbicidal action. The difference in intracellular success
between non-smooth and smooth strains suggests that intracellular survival is dependent
on cell surface components (see previous references). But exceptions to this rule do
exist, as seen with B. canis and B. ovis, which are naturally occurring, virulent nonsmooth strains, and B. neotomae, which is an avirulent smooth strain (FAO/WHO 1986;
Smith and Ficht 1990; Baldwin and Winter 1994; Sangari and Aguero 1996; Kulakov et
al. 1997). The mehods by which smooth and non-smooth strains of Brucella differ in
their protection from intracellular bactericidal mechanisms appear to be complex, and not
solely dependent on bacterial surface structure. Evidence to this point is given by
Kulakov et al. (1997), who found that B. suis and B. melitensis non-smooth mutants are
able to withstand acidic pH as efficiently as non-mutated smooth strains.
The O-polysaccharide/antigen in smooth strains of Brucella may be found in
either an A or M epitope, both of which can be expressed on the same organism, but in
different quantities. The A epitope, examined from B. abortus, is a linear molecule
composed of 96-100 residues of α-1, 2-linked 4,6-dideoxy-4-formamido-Dmannopyranose, also known as D-Rhap4 NFo (Cherwonogrodsky et al. 1990; Perry and
Bundle 1990). The M epitope from B. melitensis is identical to the A epitope except that
it is a series of repeating pentasaccharide units containing one α-1,3-linked and four α1,2-linked monosaccharide residues (FAO/WHO 1986; Bundle, Cherwonogrodzky et al.
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1989). Brucellae of the smooth type that mutate and lose this O-polysaccharide chain
exhibit the non-smooth phenotype (Sola-Landa et al. 1998). Unlike other Gram-negative,
enterobacterial LPS endotoxins, Brucella LPS is non-pyrogenic and much less toxic to its
host, especially in the non-smooth (rough) form (Moreno, Berman et al. 1981;
Cherwonogrodsky et al. 1990; Rasool et al. 1992). In a study using human neutrophils,
Rasool et al. (1992) found that 100 times more Brucella LPS and 1000 times more lipid
A were required to elicit an equivalent lysosome release from phagocytes compared to
LPS from Salmonella typhimurium. In addition, Brucella LPS and lipid A were several
orders of magnitude less toxic than Salmonella LPS. Rasool et al. (1992) speculated that
the low biological toxicity of Brucella LPS might be a factor allowing the intracellular
survival and persistence of brucellae inside phagocytes.
1.6.2.5.2 Brucella Outer Membrane Proteins (Omp)
Brucella spp. possess three classes of outer membrane proteins (Omp). The first
class, group 1, contains two Omps of 88 and 94 kDa; group 2 includes proteins of 35-43
kDa, and is composed of two Omps, 2a (41 kDa) and 2b (43 kDa); group 3 incorporates
proteins of 16.5-34 kDa and contains Omp25 (25 kDa), and Omp31 (31 kDa) (Verstreate,
Creasy et al. 1982; Douglas, Rosenberg et al. 1984; Mayfield, Bricker et al. 1988;
Cherwonogrodsky et al. 1990; Bowden, Cloeckaert et al. 1995; Cloeckaert, Jacques et al.
1995; Cloeckaert et al. 1996a; Lindler, Hadfield et al. 1996; Vizcino, Cloeckaert et al.
1996; Edmonds, Cloeckaert et al. 2001; DelVecchio et al. 2002). The group 1 Omps are
believed to be minor components of the cell envelope, while group 2 Omps are assigned
porin structural properties (Douglas et al. 1984; FAO/WHO 1986; Smith and Ficht 1990).
Membrane proteins in group 3 are structural in nature; Omp31 is complexed to the
peptidoglycan whereas Omp25, which is highly conserved among all six Brucella
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species, is bound to the peptidoglycan and LPS (Madkour 1989). It should be noted that
while some Omps are considered major membrane components in one species, they may
only be a minor membrane constituent of another species, i.e., Omp 31 is a major protein
in B. melitensis but is absent in B. abortus (Vizcino et al. 1996). Research has confirmed
that every group of Brucella outer membrane protein elicits an antigenic response from
the host (Dubray and Bezard 1980; Mayfield et al. 1988; Limet, Cloeckaert et al. 1993,
1995, 1996a; Bowden et al. 1995; Lindler et al. 1996; Vizcino et al. 1996; Bowden,
Cloeckaert et al. 1998). Research by Edmonds et al. (2001) has confirmed the
importance of Omps to Brucella intracellular survival. They demonstrated that B.
abortus Omp25 mutants exhibited lower levels of survival in bovine macrophages and
trophoblasts compared to wild type strains.
1.6.3 Other Brucella Virulence Genes and Gene Products
Although brucellae exhibit many of the same characteristics as other intracellular
pathogens, i.e., survival and multiplication within the phagosome and inhibition of cell
signaling, the majority of genes involved in Brucella-related virulence have not been
discovered (Smith and Ficht 1990; Robertson, Kovach et al. 2000). One large step
towards identifying and confirming the presence of virulence factors and other essential
genes comes from a sequence analysis of the entire B. melitensis 16M genome by
DelVecchio et al. (2002).
Although their true importance to Brucella pathogenicity has not yet been
established, the genes, proteins and pathways listed in Table 2 likely play a role in
virulence. In common with most other bacterial species, brucellae also employ a number
of specialized enzymes, which are not necessarily thought of as virulence factors, for
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Table 2. Putative virulence-related genes, proteins or pathways in B. melitensis 16M.
Protein, Gene or
Homologous to:
Pathway Identified in B.
melitensis
Hemolysin, α-hemolysin,
hemolysin III

Reference

Adhesin protein precursors AidA-I

Sanchez, Zandomeni et al. 2001;
DelVecchio et al. 2002

DelVecchio et al. 2002

Invasin precursor

InvA of Mesorhizobium DelVecchio et al. 2002
loti and Burkholderia
cepaca

acvB

VirJ of Agrobacterium DelVecchio et al. 2002
tumefaciens

mviN

Virulence protein of
Salmonella

DelVecchio et al. 2002

Lipid IV synthesis

DelVecchio et al. 2002

UDP-N-acetlymuramoyl
pentapeptide synthesis

DelVecchio et al. 2002

Ortholog of cydB

cydB of B. abortus

Endley et al. 2001; DelVecchio et al.
2002

Symbiosis protein

Protein E of
Bradyrhizobium
japonicum

DelVecchio et al. 2002

DelVecchio et al. 2002

entD
Adaptive acid tolerance
regulatory protein

ActR of
Bradyrhizobium

DelVecchio et al. 2002

protection and repair in harsh intracellular conditions. Brucella melitensis encodes DNA
repair proteins and ion, amino acid, carbohydrate, nutrient and metal transporters, with
the exception of a ferrous iron transporter (DelVecchio et al. 2002). Protein expression
during stressful conditions has been well characterized in Brucella spp. (Lin and Ficht
1995; Phillips, Elzer et al. 1995; Kohler et al. 1996; Rafie-Kolpin et al. 1996; Kim and
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Mayfield 2000; Robertson et al. 2000; Teixeira-Gomes, Cloeckaert et al. 2000). Phillips
et al. (1995) and Elzer et al. (1996) have shown that mutation of the htrA gene results in
decreased resistance of B. melitensis and B. abortus to oxidative damage and phagocyte
killing.
In addition to the identification of coding regions for cold and heat shock proteins
in B. melitensis (DelVecchio et al. 2002), several studies have revealed increased
production of the molecular chaperones DnaK and GroEL by B. abortus and B. melitensis
under conditions of macrophage phagocytosis, acid and heat stress (Rafie-Kolpin et al.
1996; Teixeira-Gomes et al. 2000). To complement this, Kohler et al. (1996) have shown
decreased B. suis survival under conditions of macrophage phagocytosis and acid stress
when dnaK is mutated. Robertson et al. (2000) studied the activity and function of the
stress response protease Lon in B. abortus and found it may play a critical role in
turnover of heat-damaged proteins in the initial stages of infection and colonization.
With the exception of B. neotomae and B. suis biovar 2, all brucellae encounter and
scavenge highly reactive oxygen species within the phagosome primarily with a catalase
and two types of superoxide dismutases (SOD), a Fe-Mn SOD and a Cu-Zn SOD
(Bricker, Tabatabai et al. 1990; Sriranganathan, Boyle et al. 1991; Tatum, Detilleux et al.
1992; Rafie-Kolpin et al. 1996; Kim and Mayfield 2000; Teixeira-Gomes et al. 2000;
DelVecchio et al. 2002). Disabling B. abortus catalase expression through mutation of
the catalase promoter, oxyR, causes increased sensitivity of B. abortus to hydrogen
peroxide (Kim and Mayfield 2000). Moreover, virulence and level of catalase expression
appear to be positively correlated (Huddleson and Stahl 1943). And after mutation of the
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Cu-Zn SOD, Tatum et al. (1992) found that BALB/c mice were better able to control the
growth and progression of B. abortus during early stages of infection.
1.7 Limitations of the Murine and Bovine Models of Brucellosis
The ability of brucellae to survive within phagocytic cells is also a function of the
mammalian host infected, i.e., mouse, human or cow. A large difference exists between
mouse and human macrophage susceptibility to Brucella infection and persistence
(Cheers and Pagram 1979; Caron et al. 1996; Gross et al. 2000). As supported by several
studies (Zhan and Kelso 1993; Caron et al. 1994, 1996; Zhan and Cheers 1995, 1998;
Liautard, Gross et al. 1996), murine macrophages readily produce TNF-α upon infection
with live Brucella whereas human cell lines do not. It has been postulated that the
secreted TNF-α inhibitory factor is species specific, and mouse cell lines are resistant to
inhibition (Caron et al. 1996; Liautard et al. 1996). This may help to explain some
contradictory results regarding TNF-α production and/or inhibition seen in the literature.
In addition, while Brucella avoids the bactericidal activity of IFN-γ-induced human
monocytes, it is regularly cleared in mouse macrophages induced in the same manner
(Stevens et al. 1992; Zhan and Cheers 1995; Gross, Spiesser et al. 1998; Gross et al.
2000).
Bovine phagocytes also are markedly different from their human counterparts. In
studies conducted with B. abortus smooth strain 45/0, Riley and Robertson (1984a) found
that human PMN cells were not as effective in killing phagocytized brucellae when
compared to bovine PMN cells. The difference in brucellacidal activity appeared to be
due to more extensive degranulation in bovine as compared to human PMN cells (Riley
and Robertson 1984b, a). This decreased ability to control a Brucella infection may help
explain the recurring nature of untreated human brucellosis.
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1.8 Brucella Type IV Secretion and Virulence - The vir Family
1.8.1 vir General Characteristics
In contrast to typical type I, II, III and V secretion systems which only export
proteins, Gram-negative bacterial type IV secretion systems are believed to be specialized
for the secretion of nucleoprotein complexes in addition to straight protein products such
as multisubunit bacterial toxins (Christie and Covacci 2000). As proposed by Christie
and Covacci (2000), the type IV secretion family is thought to have originated from a
system originally designed for conjugative transfer of DNA between bacterial cells.
Through horizontal transfer and association with other types of genes, different classes of
bacteria may have adapted the type IV secretion machinery to their environments, or
exploited new niches. Specifically, the type IV secretion system is used for the exchange
of protein-DNA complexes between bacteria, as seen in Escherichia F plasmid transport,
between bacteria and eukaryotic cells, as with Agrobacterium T-complex transfer to plant
root cells, and for extracellular secretion of polypeptide toxins, as in Bordetella toxin
export (Christie and Covacci 2000; Sieira et al. 2000).
Brucellae do not contain typical, complete operons for type I, II or III secretion,
however, they do encode components for sec-dependent, sec-independent, flagellarspecific type secretion systems, and type IV and V secretion systems (DelVecchio et al.
2002; Moreno and Moriyon 2002). The Brucella type IV secretion system is similar to
secretion systems in other symbionts and pathogens within α-Proteobacteriacae (Christie
and Covacci 2000; DelVecchio et al. 2002). Type IV secretion in all Brucella species,
including B. melitensis, is encoded by virB located on chromosome II (O'Callaghan et al.
1999; DelVecchio et al. 2002). Brucella virB genes are sequentially related to genes in
type IV secretion systems found in other closely related bacteria; e.g., the vir system of
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Agrobacterium tumefaciens, ptl transporter of Bordetella pertussis (Weiss, Johnson et al.
1993), cag pathogenicity island of Helicobacter pylori (Covacci, Telford et al. 1999),
dot/icm of Legionella pneumophila , virB of Rickettsia prowazekii (Christie and Covacci
2000), tra of Escherichia coli (Pohlman, Genetti et al. 1994; Christie 1997; Sieira et al.
2000), magB of Actinobacillus actinomycetemcomitans (Galli, Chen et al. 2001; Novak,
Dougherty et al. 2001), an unnamed type IV system in Rickettsia prowazekii and
exporters in Mesorhizobium, Yersinia and Xylella, (O'Callaghan et al. 1999; Ugalde
1999; Christie and Covacci 2000; Sieira et al. 2000; DelVecchio et al. 2002).
The virB regions of B. suis and B. melitensis are composed of 12 linearly
arranged open reading frames (ORF), whereas B. abortus contains an additional 13th ORF
that precedes and overlaps ORF12 (O'Callaghan et al. 1999; Sieira et al. 2000;
DelVecchio et al. 2002). There exist 2 palindromic, repeat sequences (BruRS1 and
BruRS2) in the virB region, the first is between virB1 and virB2, while the second is after
virB12 (Halling and Bricker 1994; O'Callaghan et al. 1999; Sieira et al. 2000; Boschiroli
et al. 2002). Two researchers have proven that despite this first palindrome, Brucella
virB genes are transcribed as an operon starting from virB1 (Sieira et al. 2000; Boschiroli
et al. 2002). However, some disagreement exists between these two studies as to whether
the virB operon is turned on during early stationary or early exponential phase. A
possible explanation for this discrepancy may be that the previous studies employed
different species of Brucella, namely B. abortus (Sieira et al. 2000) and B. suis
(Boschiroli et al. 2002). Using B. suis, Boschiroli et al. (2002) were the first to show virB
operon induction in response to environmental stress. By mimicking the macrophage
intracellular environment, they demonstrated that acid stress, elevated temperature (37oC)
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and nutritional deprivation were all positive regulators of virB expression. Additionally,
translation of each virB gene is thought to occur independently since possible ribosome
binding sites are found upstream of all B. suis virB genes (O'Callaghan et al. 1999).
Very little is known about the actual structure encoded by the Brucella virB
operon. However, between genera, the Brucella virB operon is closely related to the tra
system of the broad-host-range plasmid pKM101 found in E. coli and to the virB genes of
Agrobacterium tumefaciens, from which it’s name was taken (Stachel and Nester 1986;
Lessl, Balzer et al. 1992; O'Callaghan et al. 1999; Christie and Covacci 2000; Sieira et al.
2000; DelVecchio et al. 2002; Moreno and Moriyon 2002). O’Callaghan et al. (1999)
have revealed that at the protein level, the B. suis virB operon is more closely related to
the ptl operon of Bordetella pertussis than to virB of Agrobacterium or the tra system of
E.coli. But since 11 genes of the Brucella melitensis virB share sequence and
organizational similarity with the virB operon of Agrobacterium, structural and functional
characteristics of the Brucella system can be speculated (O'Callaghan et al. 1999;
DelVecchio et al. 2002). Like the Agrobacterium type IV system, the Brucella virB
probably codes for proteins that form a gated, pilus-like structure that spans the inner and
outer bacterial membranes as well as the eukaryotic cell membrane (Ward, Akiyoshi et
al. 1988; Kuldau, Vos et al. 1990; Christie and Covacci 2000). While the Agrobacterium
pilus penetrates the eukaryotic plant cell envelope from the outside, it is reasonable to
suspect the Brucella pilus would gain access to the mammalian host cell cytoplasm by
spanning the phagosome where it has been localized (Christie and Covacci 2000; Rittig et
al. 2001).
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Using functional studies of the Agrobacterium virB encoded proteins as a guide,
Brucella virB protein characteristics have been predicted (Table 3). The exact function
Table 3. Predicted function of Brucella virB operon components (adapted from
O'Callaghan et al. 1999; Christie and Covacci 2000; DelVecchio et al. 2002).
virB Gene Product Proposed function
VirB1

Trans-glycosylase

VirB2

Pilus formation

VirB3

Inner membrane protein

VirB4

Cytoplasmic protein, ATPase

VirB5

Pilus component

VirB6

Inner member protein

VirB7

Lipoprotein, forms complex with VirB9

VirB8

Inner membrane protein

VirB9

Periplasmic protein, forms complex with VirB7

VirB10

Periplasmic protein

VirB11

Inner membrane protein, ATPase

VirB12

Function unknown (no homology to other type IV proteins)

of the virB encoded secretion system in Brucella is unknown, although knockout studies
have shown the virB operon is essential for Brucella intracellular survival. Construction
of polar mutants of the entire virB operon or non-polar mutants of single virB genes, i.e.,
virB1, 2, 4, 5, 8, 9, 10 and 12, have resulted in an attenuated phenotype in every case and
almost complete elimination of brucellae from HeLa cells, human monocyte-like cell
lines and BALB/c mice in some instances (O'Callaghan et al. 1999; Ugalde 1999;
Foulongne, Bourg et al. 2000; Hong et al. 2000; Sieira et al. 2000; Comerci et al. 2001;
Delrue et al. 2001; Boschiroli et al. 2002). Comerci et al. (2001) and Delrue et al. (2001)
have shown that a functional virB operon in B. abortus and B. melitensis is necessary for
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manipulation of phagosomal trafficking, including delay or prevention of phagosomelysosome fusion and establishment of a replication niche. VirB is not thought to play a
role in B. abortus entry into the host cell since no reduction in adherence or
internalization has been observed with any virB mutation (Sieira et al. 2000; Comerci et
al. 2001).
The Brucella type IV secretion system is thought to be responsible for the export
of a virulence factor, as yet unknown, which mediates intracellular survival and
multiplication (O'Callaghan et al. 1999; Sieira et al. 2000; Comerci et al. 2001).
Materials exported by bacteria with homologous type IV secretion systems include:
interleukin-8-inducing factor by Helicobacter pylori, the T-complex by Agrobacterium
tumefaciens, pertussis toxin by Bordetella and plasmid DNA by Escherichia (Christie
and Covacci 2000). Yet, unlike Escherichia and Agrobacterium, brucellae do not contain
plasmids, and exchange of naturally occurring genetic material has never been observed
(O'Callaghan et al. 1999).
Recently, three Brucella products have been identified which are potential
candidates for virB-mediated export. The first two are non-protein products of B. abortus
identified by Canning et al. (1985, 1986) mentioned previously as GMP and adenine,
which act as inhibitors of the PMN myeloperoxidase (MPO)-H2O2 halide antibacterial
system. The second possibility, identified by Caron et al. (1996), is a protein, based on
its protease and heat sensitivities, of approximately 45 to 50 kDa released by B. abortus
that inhibits TNF-α production in a human, macrophage-like, neoplastic cell line, U937.
Either one or both of these inhibitory products may be exported by the virB system of
Brucella. However, it should be noted that O’Callaghan et al. (1999) also found a
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Brucella protein inhibitor of TNF-α release, but they acknowledged that virB mutants
were still able to inhibit TNF-α production.
1.8.2 virB1 and Virulence
This body of work demonstrates the inactivation of the first virB gene transcribed
in the virB operon, virB1. Efficient knockout of this gene was established by assessing
the survival and virulence of virB1 mutated strains of B. abortus 2308 and B. melitensis
16M in macrophage and in-vivo murine models. Little is known about the Brucella
virB1 gene and gene product, except what has been predicted by nucleotide and protein
sequence analysis and comparison to virB1 of Agrobacterium (Christie 1997;
O'Callaghan et al. 1999). The virB1 genes of B. melitensis and B. abortus are located on
chromosome II, are 717 nucleotides long with a GC content of 57 % (DelVecchio et al.
2002). By homology to VirB1 of A. tumefaciens and TraL of E.coli, the Brucella VirB1
is suspected of being a trans-glycosylase, playing a role in the formation of a pore for
extrusion of macromolecular complexes from the bacterial cell (O'Callaghan et al. 1999;
Christie and Covacci 2000; Sieira et al. 2000; DelVecchio et al. 2002). However,
whether VirB1’s role is essential to virB mediated export is under suspicion after a study
by Berger and Christie (1994) proposed that VirB1 of A. tumefaciens is supportive but
not essential for virulence (Christie and Covacci 2000).
1.9 Brucella Genetic Manipulation
Members of the genus Brucella are not naturally competent, however, they will
take up plasmid DNA after chemical treatment or electroporation (Lai, Schurig et al.
1990; Halling, Detilleux et al. 1991; Elzer, Kovach et al. 1995). In addition, brucellae do
not contain any naturally occurring plasmids (Rigby and Fraser 1989; Smith and Ficht
1990), yet, conjugative transfer of artificially introduced broad-host-range plasmids
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between brucellae, from E. coli into brucellae and from brucellae into E. coli has been
demonstrated (Rigby and Fraser 1989; Verger, Grayson et al. 1993). Genetic
complementation of all Brucella species is possible using the broad-host-range plasmid
pBBR1MCS and its derivatives (Kovach, Phillips et al. 1994; Elzer et al. 1995), which is
not integrated into the genome but stably maintained within all Brucella spp. at low copy
number (Elzer et al. 1995). Also, gene replacement by homologous recombination in
Brucella has been well established as an important method for the creation of specific invivo gene mutations (Lai et al. 1990; Halling et al. 1991; Tatum et al. 1992; Elzer,
Phillips et al. 1994; Drazek, Houng et al. 1995; Elzer et al. 1995; Phillips et al. 1995;
Sola-Landa et al. 1998; Kohler, Ouahrani-Bettache et al. 1999; O'Callaghan et al. 1999;
Sieira et al. 2000; Ugalde et al. 2000; Alvarez-Martinez, Machold et al. 2001; Boschiroli
et al. 2002).
One particular technique employed in the process of Brucella gene replacement is
gene disruption via deletion or insertion mutagenesis, a gene knockout. This process
involves cloning the gene of interest into the appropriate plasmid vector, followed by invitro mutation of the gene (Fig. 2). The mutation may be accomplished by the deletion of
a portion of the gene or insertion of a positive selectable marker, i.e., antibiotic resistance
gene (Halling et al. 1991; Madigan et al. 2000), at a particular restriction site within the
gene. Once the mutation in the gene of interest is confirmed, the mutagenized plasmid is
introduced into Brucella where it undergoes a double crossover event, replacing the wildtype gene with the mutagenized one via homologous recombination. Both gene deletion
and insertion result in a loss of gene function.
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Fig. 2. Gene disruption by homologous recombination between the wild type (virB1) and
the mutant gene (virB1::kan). The wild type gene was cloned into a suitable suicide
vector, which is not stably maintained in Brucella, and mutagenized by insertion of a
positive selectable marker (
). Transformation of the suicide vector into
Brucella results in recombination between the homologous regions of the mutated
and wild type genes leading to gene replacement, in-vivo loss of function and
expression of the selectable marker.
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As demonstrated by Halling et al. (1991), narrow host range ColE1-derived
plasmids (i.e., pBA31-R7) are incapable of replication in Brucella spp. and become
suicide vectors when they contain Brucella DNA. In some instances, homologous
recombination occurs between the vector and the Brucella genome enabling gene
replacement studies. One important note regarding ColE1-derived plasmid nomenclature
is the common practice of referring to ColE1-based plasmids as pMB1-derived, and vice
versa. The exact basis for this confusion is unknown, however, it is likely that since both
types of E. coli based plasmids share many of the same properties, i.e., colicin production
and immunity, mobilization via the F-factor, mode of replication and same
incompatibility group, they are considered similar enough to be used interchangeably
(Bolivar 1979; Bhagwat and Person 1981; Sambrook, Fritsch et al. 1989). In line with
this uncertainty, many studies have successfully employed pMB1-based suicide vectors
in Brucella gene replacement studies, i.e., pGP704, pUC18, pBluescript II, pUC19 and
pUC4k (Sola-Landa et al. 1998; Kohler et al. 1999; O'Callaghan et al. 1999; Ugalde et al.
2000; Alvarez-Martinez et al. 2001). In addition, at least two such gene replacement
studies have found that the cloning vector pGEM-T, created by Promega Corp. (Madison,
WI), also functions as an efficient suicide vector in brucellae (Sieira et al. 2000;
Boschiroli et al. 2002). PGEM-T is a pMB1-based cloning vector with a mutation in the
origin of replication RNAI binding region, thereby making it neither like pMB1 nor
ColE1 (Promega Corp., personal communication). Research in the present work employs
pGEM-T as a Brucella gene-cloning vector and suicide plasmid for in-vivo gene
replacement.
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Another technique that has been widely used for Brucella gene disruption is invivo transposon mutagenesis, mainly employing a Tn5-based transposon (Smith and
Heffron 1987; O'Callaghan et al. 1999; Foulongne et al. 2000; Hong et al. 2000; Lestrate,
Delrue et al. 2000; Endley et al. 2001). This type of mutagenesis, although not directed
at a specific locus, has been employed in the discovery of Brucella genes responsible for
virulence and pathogenesis. However, because the B. melitensis 16M genome has been
sequenced and potential virulence factors identified, a targeted, systematic approach to
gene knockout may now be more productive.
1.10 Transposition
Transposition is the process by which a piece of DNA, a transposable element, is
translocated from one site to another by an enzyme known as a transposase (Madigan et
al. 2000). Three types of transposons are currently known to exist: insertion sequences
(IS), composite transposons (Tn), and certain types of viruses such as Mu (Bennet 1991;
Maloy, Cronan et al. 1994; Atlas 1997). Transposition, as described above, involves the
use of a transposon, which is a gene or set of genes that code for structural proteins,
usually 2000-20000 base pairs long, flanked by short inverted terminal repeats, as seen in
ISs (Atlas 1997; Madigan et al. 2000). Examples include the transposons Tn5 and Tn7,
which confer resistance to kanamycin and neomycin, and Tn9, which contains a
chloramphenicol resistance gene (Smith and Heffron 1987; Atlas 1997; Madigan et al.
2000). Transposition of a transposable element can occur by either a conservative or
replicative manner. As it’s name implies, replicative transposition is the translocation of
a copy of a transposable element to a new location, resulting in two copies of the element,
one at the original site and one at the new site. Conservative transposition, however,
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involves the excision of the transposable element from its original location and
reinsertion at a new site (Madigan et al. 2000).
Minimally, transposition requires the presence of inverted or direct repeats that
flank transposable elements, and the transposase, which recognizes and cleaves the
flanking sequences and then ligates the transposable element at it’s new location. At
least two models exist which explain the conservative mechanism of transposition. In the
first model, proposed by Arthur and Sherratt, and Shapiro, transposase makes single
stranded cuts in both the donor and recipient DNA (as reviewed by Bennet 1991). A
transposition cointegrate is then formed, known as a “Shapiro intermediate,” that may
resolve through the cleavage of the second donor strand and gap repair.
The second model, proposed by Douglas Berg, known as the cut-and-paste
mechanism (Fig. 3) involves the complete release of the transposon from the donor DNA
by transposase enzymes without a cointegrate intermediate (as reviewed by Bennet
1991). The Berg, cut-and-paste model of conservative transposition, is now widely held
as the correct mechanism for the simple insertion of many composite transposons and
insertion sequence elements, including Tn7 and Tn10. The cut-and-paste model of
transposition is believed to involve the formation of a nucleo-protein complex, where
donor and target DNA and several transposase enzymes interact to carry out a strand
transfer reaction (Bainton, Gamas et al. 1991; Bainton, Kubo et al. 1993; Craig 1995,
1996; Sarnovsky, May et al. 1996).
1.11 In-Vivo Versus In-Vitro Transposon Mutagenesis
The basic principals behind both in-vivo and in-vitro transposon
mutagenesis are fundamentally the same: a transposable element is translocated from one
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Fig. 3. Tn7-based transposon mutagenesis. For simplicity, the transposase enzymes are
not shown. Within a DNA-protein complex, transposase nicks the donor and target
DNA (solid arrows pointing to gaps), releasing the transposon flanked by insertion
sequences (IS) and mediates the insertion into the donor and strand transfer reaction.
The cell’s DNA repair mechanisms fill-in and ligate the gap left by strand transfer,
which results in the formation of a 5 base pair repeat on both sides of the inserted
transposon (Maloy et al. 1994).
location to another (with or without replication). But, as their names imply, the major
difference between the two lies in whether the transposition reaction occurs
intracellularly. With in-vivo transposition, a transposable element is introduced into a
microorganism, via plasmid, phage, etc., where it either uses the host’s transposition
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machinery or it codes it’s own transposase enzymes for the process of transposition. In
this system, the transposon may theoretically choose to insert anywhere in the host’s
available genome. In-vivo transposon mutagenesis of Brucella has been used
successfully for at least 15 years in search of Brucella virulence genes. Smith and
Heffron (1987) first mutagenized the Brucella abortus genome using a Tn5-based system
encoded on a plasmid and on a bacteriophage. Numerous studies of Brucella spp.
followed which also employed an in-vivo Tn5-based system (Jumas-Bilak et al. 1998a;
Foulongne et al. 2000; Hong et al. 2000; Lestrate et al. 2000; Delrue et al. 2001; Endley
et al. 2001).
In contrast to the in-vivo system, in-vitro transposition is a cell-free process. Invitro transposition was first developed by Bainton et al. (1991) to insert a Tn7-based
transposon into the genome of E. coli. In order to mimic the intracellular environment,
the Tn7-based, in-vitro method requires the addition of a target DNA, Mg2+, ATP, and the
appropriate transposase proteins, TnsA, TnsB, TnsC, and TnsD (Bainton et al. 1991,
1993; Craig 1996). Originally, given the appropriate enzymes, Tn7 would preferentially
insert at specific sites in a genome (attTn7 sites). However, an artificial mutation in the
TnsC enzyme has allowed random targeting of a given genome with Tn7 (Stellwagen and
Craig 1997). This type of in-vitro mutagenesis system is important for Brucella genetics
because it now allows targeted transposition of genes that have been cloned into suitable
vectors.
1.12 The Current Study
This thesis describes the application of a rapid, simplified method of gene
disruption in the genus Brucella known as in-vitro transposition. The bacterial
transposon, Tn7, found on a donor plasmid, pGPS3, created by New England Biolabs
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(Beverly, MA), was used, in-vitro, to insert a selectable marker expressing kanamycin
resistance into the virB1 gene of B. abortus 2308, which had been cloned by PCR into a
Brucella suicide vector, pGEM-T. This construct was then used for the in-vivo
replacement of the wild type virB1 gene from virulent strains of B. melitensis 16M and B.
abortus 2308, resulting in null mutations. The two virB1 mutant strains of Brucella
created, BM29-106, which was derived from B. melitensis, and BA29-6, which was
derived from B. abortus, were used to infect murine macrophages and BALB/c mice. An
analysis of Brucella mutant survival compared to wild type at several time points was
then performed. Reliable gene disruption of the virulence gene virB1 was examined in
the present study to scrutinize the efficacy of in-vitro, Tn7-based transposition in the
evaluation of Brucella genes that may hold promise for the development of vaccine
strains of Brucella.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Bacterial Strains, Plasmid Vector Construction and Growth Conditions
Original Brucella strains used in this study include B. melitensis 16M and B.
abortus 2308 obtained from Dr. Elzer of the Department of Veterinary Science at
Louisiana State University (Baton Rouge) (Table 4).
Table 4. Bacterial strains and plasmids used in this work.
Strains or plasmids

Relevant characteristic(s)

Source

Strains
Brucella melitensis 16M

Wild type, virulent, smooth

Brucella abortus 2308

Wild type, virulent, smooth

BA29-6

Elzer 2002b
S

B. abortus 2308 virB1 mutant, Amp ,
Kan

BM29-106

Elzer 2002b
This work

R

B. melitensis 16M virB1 mutant, AmpS, This work
KanR

Escherichia coli DH5α-MCR Host for pGEM-T and its derivatives

Invitrogen
(Carlsbad, CA)

Plasmids
pBBR1MCS

Broad-host-range cloning vector, CmR

pBBR1MCS::kan

Tn7-based, kanamycin transposon from This work
pGPS3 transposed into pBBR1MCS

pGEM-T

Gram-negative host cloning vector

Promega

pGEMT-virB1

0.75 kb virB1 PCR product from B.
abortus 2308 cloned into pGEM-T

This work

pBAvirB1::kan-29

Tn7-based, kanamycin transposon from This work
pGPS3 transposed into the virB1 gene
of pGEMT-virB1

Elzer 2002b

All brucellae were grown in one of the following media: 1) Brucella broth (Difco
Laboratories, Detroit, MI), 2) Tryptic Soy Broth (TSB) (Difco Laboratories), or 3) SOCB media (6% TSB, 10mM NaCl, 2.5mM MgCl2, 10mM MgSO4, 20mM glucose, pH to
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6.8-7.0) at 370C with constant shaking. Solid media used for Brucella culture included
Schaedler Agar (SBA) (BBL/Becton Dickinson, Cockeysville, MD) plates supplemented
with 5% defibrinated bovine blood and incubated at 37oC in a 5 % CO2 atmosphere.
Inoculation doses for each strain were prepared as previously described (Elzer et
al. 1994). Escherichia coli DH5α-MCR (Table 4) were grown on Luria Butani (LB)
media (10g tryptone, 5g yeast extract, 5g NaCl per 1000ml H20) + 1.5% agar at 370C or
in LB broth at 370C with constant shaking. When appropriate, the following antibiotics
or chemicals were added to the following final concentrations: kanamycin 50 µg/ml
(Sigma, Chemical Co., St. Louis, MO); ampicillin 100 µg/ml (Sigma); chloramphenicol
30 µg/ml (Sigma); IPTG 0.5mM (Amresco, Solon, OH); X-Gal 80 µg/ml (Amresco).
The E. coli compatible cloning vector pGEM-T (Table 4) was used to construct plasmids
containing the virB1 gene of B. abortus 2308 as per the manufacturer’s instructions. The
broad host range vector pBBR1MCS (Table 4) that carries a chloramphenicol resistance
gene (CmR) was also obtained from Dr. Philip Elzer of LSU (Kovach et al. 1994).
2.2 Isolation and Preparation of Brucella DNA
For Brucella chromosomal DNA isolation, 5-10ml TSB was inoculated with the
appropriate species of Brucella and grown overnight with shaking at 37oC. The culture
was pelleted and resuspended in 300µl of phosphate buffered saline (PBS). An
equivalent volume of chloroform was added and the entire tube was mixed on a rocker
for 30-60 minutes. One hundred seventy five microliters of 50mg/ml lysozyme
(Invitrogen) was added and allowed to sit, with occasional mixing, for 30-60 minutes at
37oC. Three microliters of 20mg/ml proteinase K (Invitrogen) was added and incubated
for 30-60 minutes at 37oC. Ten percent sodium dodecyl sulfate (SDS) (Sigma) was
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added to a final concentration of 1% and incubated at 65oC for 5 minutes with occasional
mixing. An equal volume (500ul) of phenol:chloroform (25:24 ratio) (Sigma) was added
and mixed well but gently. This mixture was centrifuged at 10,000 x g for 5-10 minutes.
The upper layer was removed with a wide bore 200µl pipette tip and extracted a second
time with an equal volume of phenol:chlorform. After the second phenol:chloroform
extraction, an equal volume of chloroform was added, the mixture was centrifuged at
10,000 x g for 2 minutes and the chloroform was removed and discarded. A 1/10 volume
of 3M sodium acetate (Sigma) plus a 2X volume of 95% ethanol was added and allowed
to precipitate overnight at –20oC. The mixture was centrifuged and the liquid was
decanted or pipetted out and discarded. The Brucella DNA was resuspended in 500µl
Tris-EDTA (TE), pH 8.0, and treated with 10µl of 50mg/ml RNaseA (Invitrogen) for 1
hour at 37oC. A 1/10 volume of 3M sodium acetate plus a 2X volume of 95% ethanol
was added and the DNA was allowed to precipitate overnight at –20oC. The mixture was
centrifuged and the liquid was decanted or pipeted out and discarded. The DNA was
resuspended in 300-500µl TE. Brucella DNA yield was typically 150-300 mg/ml per
isolation.
2.3 Transposon Mutagenesis and Creation of Suicide Plasmid
The Tn7 based GPS-Mutagenesis System (New England Biolabs) was used,
according to the protocol provided, to insert a KanR cassette randomly into pBBR1MCS.
Mutagenized pBBR1MCS (pBBR1MCS::kan) was transformed into E. coli DH5α-MCR
cells as described in the Invitrogen transformation protocol. Transformants carrying the
plasmid pBBR1MCS::kan were selected on LB + kanamycin (50 µg/ml) +
chloramphenicol (30 µg/ml). Plasmid DNA was isolated by the alkaline lysis method
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(Sambrook et al. 1989) and by using a plasmid miniprep kit (Qiagen-Operon, Valencia,
CA) and suspended in sterile, deionized H2O. The virB1 gene fragment from B. abortus
2308 was generated by the polymerase chain reaction (PCR) using virB1F and virB1R
primers (Table 5) and ligated, with DNA ligase, into the plasmid vector pGEM-T at a 1:1
molar ratio of virB1 PCR product to pGEM-T vector following the protocol provided by
Promega.
Table 5. Primers used for PCR and sequencing
Primer
virB1F

Sequence
5’-AGGAGACGATCCTATGGTGC-3’

virB1R

5’-GTGCCTGATCGGATGATGG-3’

N-primer 5’-ACTTTATTGTCATAGTTTAGATCTATTTTG-3’
S-primer

5’-ATAATCCTTAAAAACTCCATTTCCACCCCT-3’

AmpF

5’-TCATCCATAGTTGCCTGACTCC-3’

AmpR

5’-GTATTCAACATTTCCGTGTCGC-3’

The PCR parameters for virB1 amplification using virB1F and virB1R are given
below (Table 6). The virB1 PCR product plus vector, pGEM-T + virB1 (pGEMT-virB1),
was transformed into E. coli DH5α-MCR cells and 100-200 µl of the transformantion
mixture was plated on LB + 1.5% agarose plates containing ampicillin (100µg/ml) +
IPTG (0.5mM) + X-Gal (80µg/ml). After incubation for 10-24 hours at 37oC, white
colonies were chosen as successful recombinants which were inoculated into LB broth +
ampicillin (100 µg/ml) and grown overnight. One and a half milliliters of each broth
culture was centrifuged for 30 seconds at 10,000 x g and plasmids were isolated using the
Qiagen-Operon plasmid miniprep kit. Purified plasmids were suspended in sterile,
deionized H2O. Correct virB1 insertion into pGEM-T was confirmed by restriction
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endonuclease digestion of purified plasmids using the restriction enzyme RsaI (New
England Biolabs).
Table 6. PCR conditions used with the virB1 and Amp primers
Time (min) Temperature (oC) Repeat
0:30

95

1X

0:30

95

30X

0:30

58

2:00

72

10:00

72

1X

∞

4

Holding
Temp

Correct forward or reverse insertion gave the following size bands when run in a 1%
agarose gel for one hour at 90 V and stained with ethidium bromide (0.3 µg/ml) (Sigma):
Forward insertion = 1414 and 2336 base pairs; Reverse orientation insertion = 1686 and
2064 base pairs (Fig. 4).
Ten plasmids were chosen and reconfirmed by restriction with BsgI (New
England Biolabs); correct banding pattern after restriction, indicating a forward insertion
= 3381 and 370 base pairs. Confirmed pGEMT-virB1 plasmid DNA concentration was
measured with a Pharmacia Biotech, UV/Visible spectrophotometer. One microgram of
the confirmed pGEMT-virB1 plasmid was mutagenized using the GPS-M transposon
system according to the protocol provided with the kit. One microliter and 10µl of the
mutagenesis reaction were transformed into E. coli DH5α-MCR cells, plated on LB +
kanamycin (50 µg/ml) and incubated overnight at 37oC. Transformants carrying the
plasmid pGEM-T + virB1 + pGPS3 (pBAvirB1::kan) were selected on LB agar plates +
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kanamycin (50 µg/ml). Plasmid DNA was isolated by the alkaline lysis method and by
using the Qiagen-Operon plasmid miniprep kit and suspended in sterile, deionized H2O.
Forward orientation insertion

Reverse orientation insertion

RsaI

RsaI

virB 1

virB 1

pGEM-T

RsaI

RsaI
Restriction
with RsaI

Restriction
with RsaI
1414 base pairs

1686 base pairs

2336 base pairs

2064 base pairs

Fig. 4. Possible restriction products after virB1 insertion into pGEM-T.
Plasmids were screened for the correct restriction pattern by restriction
endonuclease digestion indicating a possible 1700 base pair Tn7 cassette insertion into
virB1 using the restriction enzymes Nco I and Pst I (New England Biolabs). The
restriction pattern for a possible Tn7 insertion into virB1, after electrophoresis in a 1%
agarose gel and staining, consisted of two bands, 2485 and 2964 base pairs, while Tn7
insertion into pGEM-T would have been seen as bands of 785 and 4664 base pairs (Fig.
5). PCR was performed on plasmids that gave the correct restriction pattern using the
virB1F and virB1R primers under the previous PCR parameters (Table 6). PCR reactions
giving the correct band size of 2450 base pairs, after being run in a 1% agarose gel and
ethidium bromide staining (0.3 µg/ml) were used as templates for a sequencing reaction.
Sequencing was carried out by the di-deoxy method using a premixed sequencing reagent
(United States Biochemical/Amersham Life Sciences, Cleveland, OH). Primers N and S,
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which are provided by New England Biolabs with the pGPS3 mutagenesis system, were
used for sequencing under the PCR conditions given in Table 7.
Tn 7 insertion into virB 1
NcoI

Tn 7 insertion into pGEM-T
NcoI

PstI
R

PstI
virB 1

Kan
pGEM-T

virB 1
R

Kan
Restriction with
NcoI and PstI

R

Kan

Restriction with
NcoI and PstI

2485 base pairs
2964 base pairs

virB 1
R

Kan

785 base pairs
4664 base pairs

Fig. 5. Possible restriction products after Tn7 insertion into pGEMT-virB1.
Primers N and S anneal at the ends of the pGPS3 KanR transposon and face out
into the gene of interest. The result of sequencing for a successful Tn7 insertion was
plasmid #29 (pBAvirB1::kan-29).
Table 7. Sequencing PCR conditions used with the N and S primers.
Time (min) Temperature (oC) Repeat
1:00

96

1X

0:10

96

25X

0:05

50

4:00

60

∞

4

Holding
Temp

46

2.4 Electroporation and Gene Replacement
In preparation for electroporation, brucellae were grown in TSB overnight at 37oC
with constant, gentle shaking, centrifuged and washed 3X in ice cold, sterile deionzed
H20. The plasmids pBBR1MCS::kan and #29 were introduced into B. abortus 2308 and
B. melitensis 16M by electroporation at 2500 volts with an Eppendorf, Corp.
electroporator (Hamburg, Germany; model 2510). For most transformations, 1µg
plasmid DNA was added to 33µl (1x108 cfu/ml) of brucellae. Immediately after
electroporation 500µl of SOC-B was added to the transformation broth and the brucellae
were allowed to recover overnight at 37oC with constant, gentle shaking. Successful
transformants were chosen after plating on SBA + kanamycin (50 µg/ml) and incubation
at 37oC in a 5% CO2 atmosphere.
Brucellae that underwent successful crossover between the mutated virB1 region
found on the electroporated plasmid #29 and the Brucella wild type virB1 gene, exhibited
ampicillin sensitivity (AmpS) and KanR. This was confirmed by isolating chromosomal
DNA from the KanR brucellae and performing PCR using the previous virB1 primers.
Visualization of this PCR product from transformed brucellae on a 1% agarose gel gave
only the long product of 2450 base pairs (virB1+pGPS3 KanR transposon). The
restriction endonuclease Hind III was used to digest the amplified virB1 fragment giving
the expected band sizes of 1280 and 1170 base pairs after electrophoresis in a 1% agarose
gel (Fig. 6). A sequencing reaction was run of the mutant virB1-amplified fragments
from both suspected Brucella mutant strains, B. melitensis 16M mutant BM29-106, and
B. abortus 2308 mutant BA29-6. The virB1 portion of both mutant sequences matched
the existing virB1 sequence of B. abortus 2308 in Genebank.
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PCR of Brucella chromosomal DNA using
virB 1F and virB 1R

HindIII
Long amplicfication
product of 2450 bp
(virB 1::kan)

R

Kan

virB 1
Restriction with
HindIII

virB 1

1280 base pairs
virB 1

1170 base pairs

Fig. 6. Confirmation of virB1::Tn7 insertion by the amplification of virB1::Tn7 from
Brucella chromosomal DNA and restriction with HindIII.
2.5 Murine Phagocyte Killing Assay
Murine macrophages were harvested in the following manner. Twenty week-old
BALB/c mice were euthanized by a halothane overdose and the peritoneal body cavity
was exposed by peeling back the skin on their abdomens. Using a 6cc syringe with a
1.5”, 22 gauge needle, 4 mls of media + 1ml of air was injected into the peritoneum at the
mid-belly region. The injected media was a combination of Minimum Essential Eagle
Media (MEM) (Sigma) + 5% Fetal Calf Serum (FCS)(Sigma) + Heparin
(5U/ml)(Invitrogen). After media injection, the mouse was shaken vigorously for 1
minute and the media containing peritoneal macrophages was drawn out. The
macrophages were centrifuged for 5 minutes at 1100 rpm and 4oC and the resulting pellet
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was resuspended in 1ml of MEM media per mouse used for harvest. Viability counts
were performed by staining 100µl of macrophages with 100µl trypan blue in 800µl of
MEM media and visual counting with a hemocytometer leading to a final stock dilution
of 5x106 cells/ml. One hundred microliters of macrophages were placed in each well of a
96 well plate (5x105 cells/well) and allowed to adhere (differentiate) overnight. The next
morning, macrophages were washed 3X with 200µl of warm PBS + 0.5% FCS to remove
non-adherent cells. After the last washing, 200µl of warm MEM + 5% FCS was added to
each well. For opsonization, FCS + mouse antibodies were added at 1µl per ml of cells,
to 1x108 Brucella in MEM and incubated for 30 minutes at 37oC. Two hundred
microliters of opsonized brucellae were added to each well containing macrophages and
incubated for 2 hours at 37oC. The macrophages were washed once with MEM media
and twice with PBS-0.5 % FCS. Two hundred microliters of MEM + gentamycin
(50µg/ml) (Sigma) was added to each well and incubated at 37oC for 45 minutes to 1
hour. Macrophages in each well were washed 2X with PBS/FCS and reincubated with
MEM + gentamycin (12.5µg/ml). For each time point investigated, T0, T24 and T48 hours,
the gentamycin was washed out and deoxycholate (Sigma) was added to a final
concentration of 0.1% to lyse all macrophages. Each well was diluted with 20-180µl
PBS and plated on SBA or SBA + kanamycin (50 µg/ml). Plates were incubated for 2-3
days at 37oC in a 5% CO2 atmosphere.
2.6 Mouse Infection Assay
Both male and female BALB/c mice at 6 weeks of age were challenged
intravenously with 5x104 cfu of parental strain (B. abortus 2308 or B. melitensis 16M) or
mutant (BA29-6 or BM29-106). Infectious doses were confirmed by serial dilution
followed by plating on SBA for wild type brucellae and SBA + kanamycin (50 µg/ml) for
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Brucella mutants. Brucella in-vivo survival was assessed at 1 week and 4 weeks when
half the mice were euthanized at each time point by halothane overdose and the whole
spleen was aseptically removed. The spleen was weighed, homogenized, serially diluted
and plated on SBA or SBA + kanamycin (50 µg/ml). Plates were incubated at 37oC in a
5% CO2 atmosphere for 3 days.
2.7 Primers
Primers for amplification of virB1 from Brucella chromosomal DNA include
virB1F and virB1R that were supplied by Qiagen-Operon. The B. abortus and B.
melitensis virB1 sequences differ by only 1 base pair, therefore, virB1 primers were
chosen based on the published sequence of virB1 of B. abortus in GeneBank (Genebank
accession number AF226278). Primers AmpF and AmpR were also supplied by QiagenOperon. Primers N and S were provided by New England Biolabs for use with the GPSM mutagenesis system.
2.8 Biochemical Identification Tests
Brucella virB1 mutants and parental strains were characterized with standard
biochemical identification tests (Table 8). All virB1 Brucella mutant strains were
Table 8. Results of biochemical identification tests on BM29-106, BA29-6, B. abortus
2308 and B. melitensis 16M.
Test

B. abortus 2308 B. melitensis 16M BA29-6 BM29-106

Oxidase

+

+

+

+

Urease

+

+

+

+

Gram Stain

-

-

-

-

biochemically identical to their original parental species. Biochemical identification tests
on BM29-106, BA29-6, B. abortus 2308 and B. melitensis 16M included the following:
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oxidase (BBL/Becton Dickenson), urease (LSU School of Veterinary Science Media Lab,
Baton Rouge, LA), and Gram stain (Becton Dickson, Sparks, MD).
2.9 Statistical Analyses
For statistical comparison of two independent samples at a single time point the
student two-sample, paired t-test was used (Graphpad Instat, version 3.05). This test was
utilized in the analysis of Brucella virB1 mutant versus non-mutant survival in both the
macrophage-killing assay and the in-vivo mouse assay examining Brucella survival.
In addition, the two-sample t-test was employed for statistical assessment of virB1 mutant
versus non-mutant splenic weight due to Brucella burden. For all statistical tests, a
confidence interval of 95% (P<0.05) was considered significant.
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CHAPTER 3. RESULTS
3.1 Complementation of Brucella with pBBR1MCS::kan
The ability of brucellae to exhibit resistance to the antibiotic kanamycin after
complementation with a kanamycin resistance gene has been established previously in
several studies (O'Callaghan et al. 1999; Foulongne et al. 2000; Hong et al. 2000;
Sangari, Aguero et al. 2000; Sieira et al. 2000). However, it was necessary to confirm
that the promotor, which precedes the kanamycin resistance cassette on the transposon in
pGPS3, demonstrates reliable expression within Brucella. The broad host range vector
pBBR1MCS, which is stably maintained within all Brucella species, was mutagenized
with the GPS-Mutagenesis system giving the plasmid pBBR1MCS::kan. This construct
was then transformed by electroporation into B. melitensis 16M and B. abortus 2308
(Kovach et al. 1994; Elzer et al. 1995). The pGPS3 donor backbone contains a gene
conferring ampicillin resistance while pBBR1MCS contains a chloramphenicol resistance
gene. Successful mutagenesis, without pGPS3 backbone integration, transformation of
the plasmid into Brucella, maintenance and antibiotic gene expression was confirmed
when B. abortus 2308 and B. melitensis 16M were plated on SBA and the appropriate
antibiotics. Stable maintenance was displayed by colonies that exhibited sensitivity to
ampicillin (AmpS), resistance to chloramphenicol (CmR) and KanR (data not shown).
3.2 Creation of virB1 Brucella Mutants
A suicide plasmid was created to replace virB1 in Brucella species. This plasmid
is composed of the B. abortus 2308 gene virB1 that has been ligated into the cloning
vector pGEM-T, and mutagenized by insertion of a Tn7 based kanamycin resistance
cassette generating the plasmid pBAvirB1::kan-29 (Fig. 7).
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Tn 7-based transposon
R

(Kan )

virB 1

lacZ
f1 ori

pBAvirB 1::kan-29
Suicide vector
(5449 bp)
ori
Amp

R

Fig. 7. Brucella suicide vector, pBAvirB1::kan-29, constructed by inserting a kanamycin
resistance cassette into the virB1 gene of Brucella which had been cloned into the
vector pGEM-T.
The virB1 gene contained on this plasmid is that of B. abortus 2308, which is
almost identical (one base pair difference) in sequence to the virB1 gene of B. melitensis
16M. Transformation of B. melitensis 16M and B. abortus 2308 by electroporation with
pBAvirB1::kan-29 resulted in the isolation of KanR, virB1 mutant colonies which were
named BM29-106 and BA29-6 respectively. The designation of “29” in strain
nomenclature serves only to further classify which mutant plasmid was employed in gene
replacement, while the numbers “-106” and “-6” give the particular mutant colony from
which the strain was cultured. These two strains exhibited AmpS, verifying that the
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pGEM-T backbone, which contains an ampicillin resistance gene, was not incorporated
into the Brucella genome.
To confirm a double cross-over event and replacement of the Brucella wild type
virB1 gene with virB1::kan-29, PCR was performed on chromosomal DNA isolated from
the suspected Brucella mutants, BM29-106 and BA29-6. The size of these PCR products
was then determined by electrophoresis on a 1% agarose gel, staining with ethidium
bromide and exposure to UV light (Fig. 8). The mutant virB1 PCR amplification
products were then compared to the amplification products for wild-type virB1 from B.
melitensis 16M and B. abortus 2308 using the previously employed virB1 primers. When
amplified with the virB1 primers, the wild type virB1 genes of B. melitensis and B.
abortus are 750 base pairs in length (lanes 6 and 7 respectively). Once the wild type
virB1 gene of Brucella has been mutagenized with the Tn7-based transposon, which is
1700 base pairs long, the virB1 amplification product increases in length by 1700 base
pairs to 2450 base pairs. As seen in Fig. 5, the resulting bands of 2450 base pairs for the
virB1 mutant strains, BM29-106 and BA29-6, (lanes 3 and 4 respectively) correspond to
the disrupted virB1 genes containing the additional 1700 base pair transposon.
Lane 2 contains a virB1 PCR product of 2450 base pairs from the suicide plasmid
used for gene replacement, pBAvirB1::kan-29, which serves as a positive control
indicating the correct length of a Tn-7-mutated virB1 gene. Nucleotide sequencing of
both 2450 base pair, mutant virB1 PCR products from BM29-106 and BA29-6 confirmed
their identity as virB1 containing a Tn7-based transposon (Data not shown). Primers used
for sequencing included primer N and S, which were supplied by New England Biolabs
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with the GPS-Mutagenesis system. These primers anneal at the ends of the Tn7-based
transposon and extend out into the gene that has been disrupted.
Lane

1

2

3

4

5

6

7

8

3000 bp
2450 bp
2000 bp

850 bp
750 bp
650 bp

Fig. 8. One percent agarose gel showing PCR amplification of virB1 from BM29-106
(lane 3), BA29-6 (lane 4), B. melitensis 16M (lane 6), B. abortus 2308 (lane 7), and
pBAvirB1:kan-29 (lane 2). The virB1 gene of both mutant strains and
pBAvirB1::kan-29 is 2450 base pairs while both parental strains contain the wild type
virB1 of 750 base pairs. A 1 kb plus DNA ladder is provided in lanes 1, 5 and 8
(Invitrogen).
Sequencing, employing the N and S primers, reveals that the pGPS3 transposon was
inserted between base pairs 909 and 910 of the B. abortus 2308 wild type virB1 gene
(Genebank accession number AF226278).
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To further ensure the ampicillin containing, vector backbone of pBAvirB1::kan29 was not integrated into either the B. melitensis or B. abortus genome with the virB1
gene, PCR was performed on chromosomal DNA isolated from the mutants BM29-106
and BA29-6, using primers for the ampicillin resistance gene, AmpF and AmpR, as well
as a combination of N or S primers and virB1F and virB1R primers (Fig. 9).
Lane

1

2

3

4

5

6

7

8

9

10

3000bp
2400bp
2000bp

1000bp
800bp
650bp

Fig. 9. One percent agarose gel showing PCR amplification of ampicillin gene from:
pBAvirB1::kan-29 (lane 1) using ampicillin primers (Amp product size 800bp), B.
abortus 2308 virB1 mutant (lanes 2, 4 and 5) and B. melitensis 16M virB1 mutant
(lanes 6, 7 and 8) using both Amp primers (lanes 2 and 6) and one Amp primer with
either N or S primer (lanes 4-5 and 6-7). Lane 9 shows PCR of pBAvirB1::kan-29
using one Amp primer (reverse) and the N primer (2400bp). Lanes 3 and 10 contain
a 1kb+ DNA ladder (Invitrogen).
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No resulting bands were seen in lanes 2, 4, 5, 6, 7, and 8, which would be indicative of
vector integration using genomic DNA from BM29-106 and BA29-6. As positive
controls, the original suicide plasmid pBAvirB1::kan-29, which contains an ampicillin
resistance gene, was PCR amplified using the AmpR and AmpF primers (lane1) and
using the AmpR primer and N primer in conjunction (lane 9). All PCR products were
run on a 1% agarose gel, stained with ethidium bromide and exposed to UV light.
3.3 Increased Brucellacidal Activity of Murine Macrophages Against virB1 Mutants
To assess whether a nonfunctional virB1 gene will cause B. abortus and/or B.
melitensis to become more susceptible to the bactericidal activities of the murine
macrophage, a series of murine phagocyte killing assays were run. Isolated murine
macrophages were infected with BM29-106, BA29-6, B. abortus 2308 and B. melitensis
16M at a ratio of 100 brucellae per macrophage in 96 well plates. At time points of 0, 24
and 48 hours, infected macrophages were lysed, their intracellular brucellae were serially
diluted, plated on SBA and incubated at 37oC in a 5% CO2 atmosphere. Results of these
experiments are represented graphically in Fig. 10. The differences between both
parental and mutant strains of Brucella were statistically significant at a confidence
interval of at least 95% (P<0.05) for both time points (24 and 48 hours). The disparity
between B. melitensis 16M and BM29-106 intracellular survival increased steadily over
48 hours. Compared to wild type B. melitensis 16M, BM29-106 survival decreased
rapidly by 24 hours post-infection (t=24) to a level 73% lower than the wild type
(P<0.01, n=6), and by 48 hours (t=48), BM29-106 intracellular survival had fallen >98%
below wild type B. melitensis (P<0.01, n=6).
A similar pattern was observed between B. abortus 2308 and its virB1 mutant,
BA29-6, for which every mean comparison was statistically significant. By 24 hours
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Fig. 10. Results of the murine macrophage killing assay assessing the survival of BM29106 (box) and BA29-6 (star) versus their parental strains, B. melitensis 16M
(diamond) and B. abortus 2308 (triangle) over a period of 48 hours.
post-infection (t=24) the average wild type B. abortus survival rate was 10% greater than
for its mutant, BA29-6 (P<0.05, n=6). By 48 hours post-infection (t=48), the average
BA29-6 population had dropped to 98% of wild type B. abortus 2308 (P<0.01, n=6).
3.4 Virulence and Survival of Brucella virB1 Mutants in the Mouse Model
To assess the virulence of virB1 Brucella mutants and the capacity of the virB1
mutant strains to survive within a mammal host, 40 5-week old BALB/c mice were
intravenously infected with B. abortus 2308, B. melitensis 16M, BM29-106, and BA29-6.
Half the mice in each category (5 mice/category) were euthanized at 1 week while the
other half were euthanized at 4 weeks. This resulted in two time points for each strain of
Brucella, each containing 5 mice. Necropsy at both time points involved aseptic removal
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of the spleen, which was then weighed, homogenized, serially diluted and plated on SBA
for Brucella viability counting.
3.4.1 Spleen Mass
The average change in mass of a mouse spleen as a function of time of necropsy
for each strain of Brucella used for initial infection was calculated (Fig.11).
0.4
0.35
Spleen Mass (g)

0.3
0.25
0.2
0.15
0.1
0.05
0
1

4
Time Post-Infection (Weeks)

Fig. 11. Average mouse spleen mass assessing the virulence of each Brucella strain as a
function of the time post-infection. B. abortus 2308 (triangle), BA29-6 (star), B.
melitensis 16M (diamond) and BM29-106 (box).
According to the data, spleen mass for mice infected with B. abortus 2308 and B.
melitensis 16M wild types was greater than for mice infected with the virB1 mutants
BA29-6 and BM29-106 at both 1 and 4 weeks. Student t-tests comparing the spleen mass
of mice infected with wild type brucellae versus virB1 mutants for each time point were
statistically significant at a confidence interval of 95% (P<0.05): B. abortus 2308
average spleen mass was 87% greater than BA29-6 at 1 week (P<0.01, n=5) and 135%
greater at 4 weeks (P=0.001, n=5); average spleen mass for B. melitensis 16M was 78%
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greater than BM29-106 at 1 week (P<0.0001, n=5) and 190% greater at 4 weeks
(P<0.001, n=5). In addition, the average spleen mass for the B. melitensis 16M infected
mice from 1 to 4 weeks increased 81% and was statistically significant, (P<0.01, n=5),
while the spleen mass of BM29-106 infected mice did not significantly increase (an 11%
increase). Spleen mass for B. abortus 2308 infected mice did increase 5% from 1 to 4
weeks, which was not statistically significant; however, BA29-6 spleen mass decreased
17% over the same period at a statistically significant level (P<0.05, n=5).
3.4.2 Spleen Brucella Burden
The average mouse spleen Brucella burden for each of the 4 Brucella strains is
graphically represented in Fig. 12 as Brucella colony forming units (cfu) per spleen.

Brucella cfu/spleen (log10)

1.00E+06
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1.00E+04

1.00E+03
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4

Time Post-Infection (Weeks)

Fig. 12. Results of the in-vivo mouse model of Brucella infection assessing the survival
of BM29-106 (box) and BA29-6 (star) versus their parental strains, B. melitensis 16M
(diamond) and B. abortus 2308 (triangle) in-vivo over a period of 4 weeks.
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The mean cfu/spleen for both virB1 mutants, BM29-106 and BA29-6, was considerably
below (1.4 to 2 logs lower) their parental counterparts by 4 weeks post-infection and
statistically significant (P<0.05, n=5) at both time points. As represented in the graph, a
comparison between B. melitensis 16M and BM29-106 spleen colonization reveals that at
1-week post-infection, BM29-106 colonized the mouse spleen at a statistically significant
lower level, 0.68 logs less than its parental strain (P<0.05, n=5). The gap between these
two strains, in regards to spleen Brucella burden, increaseed at 4 weeks to 1.4 logs, which
maintained statistical significance (P<0.05, n=5). The disparity between B. abortus 2308
and its virB1 mutant counterpart, BA29-6, was even greater at both time points. Analysis
reveals that at 1-week post-infection the splenic colonization of the B. abortus 2308 virB1
mutant (BA29-6) was 0.82 logs less than its parental strain, which is statistically
significant (P<0.01, n=5). By 4 weeks post-infection BA29-6 remained at a statistically
significant lower level (2.06 logs lower) in the mouse spleen than wild type B. abortus
2308 (P<0.01, n=5).
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CHAPTER 4. DISCUSSION
4.1 Experiment Summary
The mechanisms of Brucella survival and virulence are not fully understood. The
success of Brucella, however, appears to be a product of its ability to endure and thrive in
the normally bactericidal environment of the phagocyte. Many of the past studies into
the novel mechanisms that allow Brucella this environmental niche have relied upon the
creation of null mutations. At least two methods have been employed in the construction
of null mutations leading to Brucella knockout strains: In-vivo, random transposition
using Tn5-based transposons, and in-vitro gene disruption by insertion of a selectable
marker at an endonuclease restriction site. A third method of gene mutation, performed
in-vitro, is presented in the current study. GPS-M is a Tn7-based, in-vitro transposition
system designed by New England Biolabs for the targeted inactivation of genes with a
kanamycin resistance cassette that can be used in Gram-negative organisms. This thesis
described the use of the GPS-M system for insertional mutation of a Brucella virulence
gene, virB1.
The central aim of this study was to investigate the efficiency and utility of an invitro, Tn7-based transposition system for the inactivation of genes within members of the
genus Brucella. Initially, the plasmid pBBR1MCS, which is stably maintained in all
Brucella species (Elzer et al. 1995), was mutagenized by the insertion of a Tn7-based
transposon containing a kanamycin resistance cassette producing the plasmid
pBBR1MCS::kan. Expression of kanamycin resistance by Brucella indicated the reliable
functioning of the foreign, Tn7-based promotor within brucellae. The virulence gene
virB1, found in B. melitensis 16M and B. abortus 2308, was then cloned into a vector
where it also was mutagenized by the insertion of a Tn7-based transposon, creating the
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suicide plasmid pBAvirB1::kan-29. This construct was used successfully to replace the
wild-type virB1 gene in-vivo by homologous recombination, generating virB1 mutant
strains of B. melitensis 16M (BM29-106) and B. abortus 2308 (BA29-6). PCR and
nucleotide sequencing confirmed disruption of the B. melitensis and B. abortus virB1
loci.
The efficacy of gene inactivation via in-vitro transposition and the pathologic
significance of the Brucella virB1 gene were evaluated by infection of murine peritoneal
macrophages and BALB/c mice with the virB1 mutants BM29-106, BA29-6 and their
parental strains. Results of these experiments suggest that in-vitro Tn7-based
transposition is an effective method for the creation of null mutations. Both virB1 mutant
strains exhibited attenuated virulence and lower levels of survival compared to wild type
B. melitensis 16M and B. abortus 2308 in both the macrophage and murine models. The
survival of Brucella mutants in both models and at all time points were significantly
lower (P<0.05) than wild type.
4.2 virB1 Mutation in Other Species Results in Attenuation of Virulence
Several studies have investigated the significance of the virB operon to the
pathogenicity of Brucella (O'Callaghan et al. 1999; Ugalde 1999; Foulongne et al. 2000;
Hong et al. 2000; Sieira et al. 2000; Comerci et al. 2001; Delrue et al. 2001; Boschiroli et
al. 2002), however, most of what is known about the virB operon has come from work
with other type IV secretion systems, especially the Agrobacterium virB complex. In
mutational studies with Agrobacterium, a plant parasite that causes crown gall disease,
Berger and Christie (1994) discovered that virB1 is a non-essential virulence factor or
transport component for eukaryotic cell transformation (Christie 1997; Christie and
Covacci 2000). While non-polar mutations of virB2-virB11 resulted in avirulent strains
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of A. tumefaciens, mutation of only virB1 decreased the efficiency of DNA transfer from
bacterium to plant by 1 to 3 orders of magnitude compared to bacteria with a wild type
virB1 gene (Berger and Christie 1994; Fullner 1998). Similar results (10-100 fold
decrease in conjugation or transfer frequency) were found in other virB1 relatives: “gene
19” of plasmid R1 (Bayer, Eferl et al. 1995) and traL of plasmid pKM101 (Winans 1985
as cited in Berger and Christie 1994; Pohlman et al. 1994; Baron, Llosa et al. 1997). As
asserted by Baron et al. (1997), this decrease in virulence, as opposed to complete
avirulence, may signal that transglycosylase-like activities are not essential for functional
type IV machinery, or that there are redundant systems present (Boschiroli et al. 2002).
In support of this theory, the type IV secretion systems of Bartonella henselae
(Schmiederer, Arcenas et al. 2001), Legionella pneumophila, Bordetalla pertussis,
Rickettsia provawekii, IncW plasmid R388 and Helicobacter pylori (Bayer et al. 1995;
Baron et al. 1997; O'Callaghan et al. 1999; Segal, Russo et al. 1999; Christie and Covacci
2000; Sieira et al. 2000) lack a virB1 homologue entirely. And in the case of B.
melitensis 16M, a membrane-bound lytic murein transglycosylase is encoded on
chromosome II immediately before the virB operon (DelVecchio et al. 2002).
Apart from sequence and protein similarity, it is not known to what extent the
Agrobacterium and Brucella VirB1 proteins are homologous. For instance, VirB1 of
Agrobacterium, after translational processing, produces 2 proteins, VirB1 and VirB1*,
believed to have independent properties: 1) protein VirB1 is a transglycosylase which
cleaves the glycosidic bonds of peptidoglycan to create a pore for VirB transporter
assembly (Dijkstra and Keck 1996; Mushegian, Fullner et al. 1996; Baron et al. 1997;
Christie 1997; Zupan, Ward et al. 1998; Christie and Covacci 2000; Llosa, Zupan et al.
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2000), while 2) protein VirB1* is secreted outside the bacterial cell and associates with
the bacterial membrane, VirB9, and possibly the plant cell wall to initiate or participate in
pilus formation (Baron et al. 1997; Christie 1997; Chumakov and Kurbanova 1998, 1999;
Llosa et al. 2000). A comparison of VirB1 homologues in Agrobacterium and E. coli
reveals that Brucella VirB1 also contains an N-terminal signal sequence cleavage site
required for export and amino acid motifs consistent with lytic transglycosylases
(Mushegian et al. 1996; O'Callaghan et al. 1999). However, there is currently no
literature that suggests Brucella VirB1 is processed, as is the Agrobacterium VirB1
homologue, into 2 independent proteins.
4.3 virB1 Mutation via Tn7-Based Transposition Results in Brucella Attenuation
In this study, mutation of virB1 with a Tn7-based transposon produced strains of
Brucella that were attenuated in the murine macrophage model of infection. In this
model, at 24 hours post-infection, the survival of the B. abortus virB1 mutant (BA29-6)
was 90% of its wild type while the B. melitensis virB1 mutant (BM29-106) survival was
only 27% of its corresponding parental strain. By 48 hours in the macrophage model
both mutant survival rates had dropped to or below 2% of their wild types. The current
work shows a statistically significant (at least P<0.05) 1-2 log decrease in Brucella
intracellular survival at 48 hours in the murine macrophage model and by 4 weeks in the
mouse model when the Brucella virB1 gene is disrupted. These results are in agreement
with previous findings (Berger and Christie 1994; Pohlman et al. 1994; Bayer et al. 1995;
Baron et al. 1997; Fullner 1998) that inactivation of other virB1 homologues
(Agrobacterium virB1, “gene 19” of plasmid R1, and traL of plasmid pKM101) results in
a 1-3 log decrease in microbial survival. This suggests that the B. melitensis 16M and B.
abortus 2308 virB1 gene products, like the Agrobacterium VirB1 protein, may not be
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essential for virulence or intracellular survival up to 4 weeks post-infection in the mouse
model of infection.
Assuming VirB1 is not involved in cell-macrophage contact or entry but in
intracellular survival and multiplication, as several studies have suggested (O'Callaghan
et al. 1999; Hong et al. 2000; Sieira et al. 2000; Comerci et al. 2001; Delrue et al. 2001;
Rittig et al. 2001; Boschiroli et al. 2002), attenuated strains of Brucella would be more
susceptible to the bactericidal mechanisms of the phagocyte, and thus give lower 24 and
48 hour macrophage intracellular survival counts and lower splenic burdens at 4 weeks
post-infection. Evaluating both experimental portions of this series, it can be concluded
that Tn7-based in-vitro transposition is an efficient means for creating mutated strains of
B. melitensis 16M and B. abortus 2308. The current virB1 mutant strains of Brucella are
less virulent/replication efficient compared to their respective wild type species,
evidenced by their decreased survival in both model systems of infection.
4.4 The Importance of the Macrophage and Murine Models of Infection
The macrophage model is important to the understanding of Brucella infection for
two reasons: 1) Brucellae depend on the protection afforded them by their intracellular
lifestyle within the relatively long-lived macrophage. In-vitro studies suggest that serum
components are able to kill brucellae, particularly in cattle (Enright 1990). Outside the
phagocyte, brucellae are exposed to antibodies, especially IgG, that may enhance
phagocytosis and macrophage brucellacidal activity (Ralston and Elberg 1971 as cited in
Nicoletti and Winter 1990). However, bacteremia is considered an important phase of
Brucella dissemination and the value of complement to in-vivo brucellacidal action is not
known or well understood. 2) Brucellae exploit macrophages as one of their main
vehicles of distribution throughout the mammal host. Brucellae are non-motile, without
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flagella, pseudopodia or fimbriae, and thus rely on their own phagocytosis and
dissemination by macrophages. The murine model of Brucella infection has been
demonstrated to be important because experimental results obtained with mice are
frequently applicable to humans and especially to ruminants such as cows, goats and
sheep, which are the main reservoirs of several Brucella species (FAO/WHO 1986).
4.5 Tn7-Based In-vitro Transposition and Vaccine Development
The underlying goal in the present study, with implications to human and
ruminant health, is the exploration of virB1-mediated Brucella attenuation in the
construction of a Brucella vaccine. Studies toward the discovery of candidates for an
effective yet safe Brucella vaccine have dominated Brucella-related literature over the
past 25 years. The problem has been approached by several angles, including
investigations into live-vaccines, whole-killed vaccines, soluble extracts containing LPS
and outer membrane proteins as vaccines, and increasing the population frequency of
genes in the host responsible for natural resistance to brucellosis (Huddleson 1947b;
Davies, Cocks et al. 1980; Dubray and Bezard 1980; Frenchick et al. 1985; FAO/WHO
1986; Nicoletti 1990; Price, Templeton et al. 1990; Zhan and Kelso 1993; Bowden et al.
1995; Drazek et al. 1995; Zhan and Cheers 1998). Although currently there is no safe
human vaccine, several exist for use in ruminants and small mammals, such as B.
melitensis Rev.1, B. abortus strain 19 and B. suis strain 2 (FAO/WHO 1986).
Lately, a promising method for vaccine development has been the creation of live,
attenuated Brucella strains of low virulence by the inactivation of genes important for
pathogenicity or survival. Three difficult hurdles on this track have been: 1) The
identification and inactivation of a gene or genes which decrease or eliminate Brucella
virulence enabling the host to produce antibodies while still effectively clearing or
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reducing the number of bacteria, 2) keeping a high level of humoral immunity towards
brucellae over a long period of time, and 3) developing a vaccine which, even if not
intended for human use, is safe for man.
The current study focuses on part of the first hurdle to vaccine development,
efficient inactivation of a virulence gene or genes. Based on the present set of
experiments, successful null mutations can be created in different Brucella species using
a Tn7-based, in-vitro mutagenesis system. While Tn5-based, in-vivo mutagenesis has
been extensively carried out using Brucella, this is the first time, to the author’s
knowledge, where a Tn7-based, in-vitro transposition system was employed with
Brucella leading to mutant strains of B. melitensis 16M and B. abortus 2308 having
attenuated virulence in the murine macrophage and mouse models.
4.6 Advantages and Applications of Tn7-based Transposition
Tn7 transposition of Brucella genes has several advantages over existing methods
of in-vitro and in-vivo gene disruption. As adapted by New England Biolabs, Tn7-based
in-vitro transposition using the pGPS3 mutagensis system inserts a transposon randomly
into the genome and does not require the presence of a specific restriction endonuclease
site within the gene of interest. Also, Tn7-based transposons exhibit target immunity,
whereby only one insertion occurs over a distance of ~190 kilobases, which ensures
single, rather than multiple gene knockouts in a cloned gene. Tn7-based transposition
can be used in-vitro, to target a specific gene cloned into a vector, while Tn5-based, invivo systems cannot be targeted towards one particular gene. In addition, in-vitro
transposition is an extremely rapid method for Brucella gene knockout. In-vivo, Tn5based mutagenesis systems require the screening of hundreds and possibly thousands of
recombinants, which is exceedingly time consuming. The entire process from
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transposition to mutant strain confirmation, using targeted gene disruption via Tn7-based
in-vitro transposition, can be performed in less than two weeks.
The in-vitro transposition system described here, in combination with the recently
published nucleotide sequence of B. melitensis 16M, has great potential value for the
study of open reading frames with no assigned functions that make up 22% of the B.
melitensis genome (DelVecchio et al. 2002). Many regulatory and virulence-associated
open reading frames, with homology in other bacterial systems, have also been identified
within the Brucella genome. Most of these loci of Brucella have never been studied in
the laboratory, some examples include: virF and virJ homologs, adhesins, invasins,
incomplete sec-dependent, sec-independent, and flagellar type III and V secretion
systems, thiamin synthesis genes, genes which code for heavy metal efflux pumps,
enterobactin, BacA (a transport pathway gene), hemolysins, histidine kinase homologs,
alkylation damage repair protein, stress-induced proteins similar to UspA of E. coli, a
probable ABC transporter for copper uptake, and a heme catalase gene (DelVecchio et al.
2002; Moreno and Moriyon 2002). Creation of Brucella mutants lacking these genes,
pathways or open reading frames could be swiftly accomplished with Tn7-based in-vitro
transposition as it is described in this study. Additionally, in-vitro transposition can
accomplish multiple Brucella gene knockouts in the same organism through the use of
different antibiotic resistance cassettes. Possible targets could include inactivation of a
putative or known pathway, such as lipid IV biosynthesis, at several important catalytic
steps instead of one, or mutation of several outer membrane proteins at the same time.
In a further assessment of this in-vitro transposition system and to examine virB1
for vaccine potential, the laboratory of Dr. Philip Elzer at Louisiana State University is
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currently evaluating the efficacy of BM29-106 in the natural host of B. melitensis, the
goat.
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